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ABSTRACT
DESIGN AND SYNTHESIS OF SIMPLIFIED ANALOGS OF THE NATURAL
PRODUCT SORDARIN AS POTENTIAL ANTIFUNGAL AGENTS

Yibiao Wu, M. Sc.
Marquette University, 2019

Invasive fungal infection is a life-threatening illness that causes high mortality,
and is especially common among patients with compromised immune systems. However,
currently there are only three major classes of clinically useful drugs capable of treating
such infections. In addition, due to the fact that drug resistance has become a serious issue
especially among patients who suffer from chronic infections, it is urgent to identify new
drug candidates, particular those of new classes.
The discovery of the natural product sordarin and its novel mechanism of action
of inhibiting fungal protein synthesis via the fungal eukaryotic elongation factor 2 (eEF2)
led to the development of a new class of antifungal agents that target eEF2. Despite the
extensive efforts of multiple pharmaceutical companies striving to identify a clinically
useful agent from this class, there has been no analog that has successfully reached clinical
trials, perhaps due to unsatisfactory pharmacokinetic profiles or limited spectra of activity.
This study mainly focused on the synthesis of a series of simplified bicyclic
sordarin analogs. By switching the parent sordarin molecule’s metabolically unstable
cyclopentane to a more metabolically stable substituent, an improved pharmacokinetic
profile could be achieved. This function-oriented synthesis approach also allows a more
facile synthesis as compared with reported total syntheses.
Two generations of novel bicyclic sordarin analogs were synthesized featuring a
Diels-Alder reaction using a functionalized silyloxy-cyclopentadiene. The 1st-generation
synthesis furnished an analog maintaining the minimum pharmacophore of a bicyclic
carboxylic acid vicinal to a nitrile or aldehyde. In subsequent studies, five different
strategies for constructing a C-2 quaternary center on the bicyclo[2.2.1]heptane core were
studied in detail, and a synthetic route featuring a stereoselective alkylation at C-2 was
developed, which gives access to more sophisticated bicyclic sordarin analogs, including

those with glycone moieties.
Five bicyclic sordarin analogs were synthesized and assessed against C. albicans,
C. parapsilosis, P. variotii and A. fumigatus. Although no antifungal activities were
observed up to 8 µg/mL, the established synthetic route will enable unique structureactivity relationship (SAR) studies that could generate promising antifungal agents
targeting eEF2.
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1.0 Background

Fungal infection caused by pathogenic fungi is now a more fatal disease than malaria
or tuberculosis, causing 1.5 to 2 million death each year1. Generally, fungal infections can
be divided into two major categories, superficial or subcutaneous infection where the
pathogenic fungi live in the skin, nail, or hair of the host, and systemic infection which is
often caused by inhalation of spores produced by invasive fungal species. The first kind of
infection is often not life-threatening and to a large extent curable by using current
antifungal drugs, however in the latter type the fungi will affect host organs or even the
CNS. Such infections are typically observed in patients who are under the influence of
immunosuppressant drugs, including many chemotherapies for cancer.
There are only three common classes of antifungal agents currently on market that are
approved to treat systemic fungal infections: the polyenes, the azoles, and the
echinocandins. (Figure 1.0.1)
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Figure 1.0.1: Representative antifungal agents of three clinically approved classes for
systemic infections

These three classes have a common feature, namely, they all ultimately affect the
integrity of the fungal cell wall or membrane, either by directly binding to or by disrupting
the synthesis of key components of the cell membrane or wall. For example, the azole class
acts by inhibiting fungal 14α-demethylase which is the enzyme responsible for converting
lanosterol to ergosterol, which in turn alters the permeability and rigidity of plasma
membranes. The inhibition thus causes changes in the permeability of the cell membrane
and eventually leads to cell lysis.2 The polyene class causes the formation of pores on
fungal cell membrane by directly binding to ergosterol embedded within.3 The
echinocandin class act as a 1,3-beta-glucan synthase inhibitor so that the fungal cell can no
longer synthesize 1,3-beta-glucan, which is a key component of fungal cell wall.4 However,
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these three classes all have different limitations in clinical use.
Severe side effects and resistance is rarely seen in the echinocandin class, however one
limitation is the fact that it’s only available via IV administration, which can be problematic
for patients who need prolonged treatment.5
The polyene class represented by amphotericin B is well-known for its severe
nephrotoxicity, which can lead to kidney failure. While the azoles generally do not have
side effects as severe as the polyene class, development of drug resistance in various fungal
species toward this type of drug has been reported more and more frequently in recent
years.5-6
Therefore, new classes of antifungal agents may provide alternative options for the
treatment of systemic fungal infections which could overcome the weaknesses of preexisting antifungal drugs, such as high cytotoxicity, lack of oral activity, and developed
drug resistance.

1.1 Sordarin and Its Medicinal Chemistry
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Figure 1.1.1: Sordarin and its aglycone sordaricin

Sordarin is a natural product isolated from the fungus Sordaria araneosa, reported in
1967 by the Swiss pharmaceutical company Sandoz7, which has a unique tetracyclic
diterpene core structure and a carbohydrate moiety (Figure 1.1.1). In the late 1990s, people
started to discover new members of this family and recognize their antifungal activities. In
the meantime, the fungal resistance toward pre-existing antifungal drugs such as
fluconazole has become more and more serious, and thus efforts to find a more potent and
stable sordarin analog against pathogenic fungi increased after 1998 when Merck and
Glaxo obtained evidence to rationalize the high selectivity of this compound toward fungi.8
Sordarin acts by selectively binding to the fungal protein eukaryotic elongation factor 2
(eEF2) which is a cofactor required for the translocation process during protein synthesis.
In a binding assay examination, ribosomes and eEF2 from 3 different species were used to
form different ribosome-eEF2 complexes, it has been shown that inhibition of protein
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synthesis by sordarin only happens significantly when fungal eEF2 is present regardless of
what species of the ribosome is used.8 Selective binding to fungal eEF2 is possible despite
the high sequence similarity between human and fungal eEF2. When a sordarin-eEF2
complex is formed it will not be able to disengage the ribosome easily, thus inhibiting the
translocation step of ribosomal protein synthesis.
Another important structural biological finding is the role of a motif of the ribosome
40S subunit called rpP0 in the development of resistance to sordarin. García-Bustos et al.8b
have shown that fungi use two strategies to counteract sordarin, mutating eEF2 or mutating
rpP0: the first type of mutant has no affinity for sordarin, and the second type of mutant
may be able to force the ribosome to distort the sordarin-eEF2 complex so that eEF2 can
still function.
The effort of building sordarin analogs has been dominated semisynthesis whereby the
original carbohydrate moiety is replaced with other groups such as the morpholino ester
reported by Glaxo.9 (Figure 1.1.2) Tremendous efforts at modifying the parent compound10
have led to the discovery of highly potent synthetic sordarins, but only a few of them
showed therapeutically useful potency in vivo and PK profile,11 and none of them have
reached clinical trials. Moreover, despite these intensive efforts, there are still several
important areas remaining to be explored, such as the modification of the sordarin core
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structure,12 which is problematic due to the inert nature of the unfunctionalized aliphatic
core, or the challenge of de novo syntheses. Novel modifications to the core structure may
lead to more potent and/or more stable sordarin analogs with the potential for clinical utility.
This is the focus of our current efforts.

Figure 1.1.2: Representative sordarin analogs

A summary of semi-synthetic or natural sordarin derivatives categorized by
different pharmaceutical companies is given below:

1.1.1

Merck

In the late 1990s, Merck published some fundamental SAR studies showing that
the sugar unit of the sordarin molecule is not essential for the inhibition of S. cerevisiae a
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non-pathogenic fungal species.13 By substituting the sugar moiety with an aliphatic chain
of optimal length, dramatic increases in antifungal activity were observed (Figure 1.1.1.1).
These alkyl ethers were later shown by Regueiro-Ren et al., in pathogenic fungal species
such as C. albicans and C. glabrata, to have MICs 1000-fold lower than to sordarin.14 This
could be due to the metabolic instability of the alkyl ether.

Figure 1.1.1.1: Merck’s semi-synthetic sordarins

Another important finding in the same study was that it is essential for the sordarin
core to have an aldehyde or nitrile group adjacent to the bridgehead carboxylic acid. Other
functional group beyond this scope abolished the antifungal activity. This pharmacophore
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can be explained with the x-ray crystal structure of sordarin-eEF2 complex reported by
Andersen,15 showing that the carboxylic acid (mediated by two water molecules) and the
aldehyde form hydrogen bonds with Glu-524 and Ala-562 respectively. (Figure 1.1.1.2)

Figure 1.1.1.2: X-ray crystal structure of sordarin-eEF2 complex

Apart from the semi-synthetic sordarin studies, another important contribution of
Merck is the discovery of the natural sordarin family member moriniafungin16 (Figure
1.1.1.3). This natural sordarin is produced by M. pestalozzioides, and has a relatively broad
antifungal spectrum that includs C. albicans, C. glabrata, and S. cerevisiae. Despite the
fact that this is the most potent natural sordarin to date, this compound did not show any in
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vivo efficacy. In a murine model of disseminated candidiasis with enhanced susceptibility
to C. albicans, Moriniafungin did not produce any reduction in the number of c.f.u. (colony
forming units), even at high doses.16

Figure 1.1.1.3: Moriniafungin
1.1.2

Glaxo

Researchers from Glaxo Wellcome (presently “GlaxoSmithKline”) developed a
series of azasordarins9, 17 represented by GW471558 (Figure 1.1.2.1), which are the most
potent semi-synthetic sordarins against Candida species to date (best MIC < 0.001 ug/mL
(C. albicans)). In all Candida species tested except for C. krusei which is intrinsically
resistant to azasordarins, azasordarins are significantly more potent than amphotericin B or
fluconazole. In addition, they also showed oral activity with relatively low dosage (ED50=
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9.0 mg/kg in mice), and they are safer to mammalian cells than amphotericin B in terms of
cytotoxicity.
In the same period, researchers from Glaxo were also able to isolate a reasonably
potent natural sordarin family member GR135402 (Figure 1.1.2.1) from a fermentation
broth of Graphium putredinis, which although is not toxic at high doses in animals, lacked
activity against a series of Candida species as well as A. fumigatus.18

Figure 1.1.2.1: Glaxo’s sordarin derivative GW135402 and azasordarin GW471558

In a rodent hepatic S9 fraction stability study, HPLC-MS analysis revealed that
the major metabolites through P450 oxidation are C-6/C-7 hydroxy or 6,7-dihydroxy
sordarin (Figure 1.1.2.2). based on this finding, an effort of reducing the complexity of the
sordarin molecule was also made by Glaxo.12 This work examined the possibility of
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whether modifying the oxidation site of P450, namely the aliphatic 5-membered ring and
6-membered rings, would increase the bioavailability, and whether a simpler structure
could maintain the pharmacophoric groups in the orientation required for antifungal
activity.

Figure 1.1.2.1: P-450 metabolite of sordarin and simplified sordarin

However, this approach showed that such a modification will lead to at least 28fold lower potency compared to the parent tetracyclic molecule (sordaricin, the aglycone
of sordarin) which in turn is already much less potent than sordarin. This is probably
because the non-bridged cyclopentane (Figure 1.1.2.1) is not able to maintain the OHC-CC-COOH dihedral angle. Based on their molecular modeling result using INSIGHT
software, although the distance between pharmacophoric groups OHC-C-C-COOH are
maintained, the dihedral angle of them has changed more than 25 degrees. (Figure 1.1.2.2)
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Figure 1.1.2.2: Geometry comparison between sordaricin and simplified sordaricin19

Since the outcome of an antimicrobial agent in vivo is a function of two important
factors, the intrinsic antimicrobial ability of the agent and the pharmacokinetic profile of
the agent,20 PK studies are an important part of preclinical development. Glaxo also
performed detailed PK studies on the sordarins, mainly with a series of sordarin derivatives
with a sugar unit containing 3’,4’-fused tetrahydrofuran ring with a methyl or an
exomethylene group21 (Figure 1.1.2.3). The compounds represented by GM237354
showed a linear correlation of efficacy with dosage as well as low cytotoxicity in mice and
rat.21b Histological observations also showed significant efficacy in the infected tissue of
immunosuppressed rats.21g
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Figure 1.1.2.3: 3’,4’-fused tetrahydrofuran derivatives
1.1.3

Sankyo

Sankyo patented a natural sordarin family member called Zofimarin22 isolated
from Zofiella marina in 1987. It showed potent in vitro activity but had no activity in vivo.
Later Sankyo patented a series of Zofimarin derivatives23 featuring an oxime ether or
thioether structure at the sugar unit position of sordarin, some of which had good in vitro
potency. (Figure 1.1.3.1)

Figure 1.1.3.1: Zofimarin and derivatives

14

Inspired by Glaxo’s azasordarin derivatives which showed promising in vivo
efficacy,9, 17, 24 Sankyo synthesized a series of N-substituted 1,4-oxazepanyl sordaricins
from Zofimarin (Figure 1.1.3.2). Those analogs are represented by R-135853, which
showed good in vitro efficacy against C. albicans (best MIC= 0.016 ug/mL), but still poor
activity against A. fumigatus (best MIC> 4 ug/mL). Later R-135853 was subjected to in
vivo efficacy examination and PK studies in mice, it had good absorption and efficacy by
oral administration, however it suffered from short t1/2 (1.1 h, oral) and rapid clearance in
IV administration.25

Figure 1.1.3.2: Synthesis of N-substituted 1,4-oxazepanyl sordaricin R-135853
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Sankyo attempted to find better sordarin derivatives by modifying the chemically
inert sordarin core skeleton through biotransformation26 (Figure 1.1.3.3). Although they
were able to hydroxylate the C-6 position of the core to give 6-hydroxyzofimarin and from
which derived 6-fluro and 6-acetoxyzofimarin, none of these compounds showed better
efficacy than the parent compound zofimarin. They soon realized that the metabolite of
sordarin in mouse was 6- and/or 7-hydroxysordarin which might have lower activity. Their
conclusion was that it might be possible to find a compound with a better PK profile if the
C-6 position can be converted to some enzymatically inert substituent.

Figure 1.1.3.3: Sankyo’s 6-oxidized (6’-oxidized in conventional numbering) sordarins
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1.1.4

Bristol-Myers Squibb

BMS did extensive SAR studies on glycosyl replacements,27 and early efforts
included 3 major categories: oxazepine derivatives, oxime derivatives, and alcohol and
ketone derivatives. Although no compounds with superior potency to previous examples
were identified, these works have confirmed the observation made by Merck earlier, that
is, when a non-cyclic glycosyl replacement is used, a nonpolar medium sized sidechain
group is needed to have good potency, which could suggest a large lipophilic pocket in the
target enzyme eEF2.
Some oxazepine derivatives (Figure 1.1.4.1)27a had a balanced antifungal
spectrum including reasonable activity against C. neoformans, and SAR studies showed
that removing the hydroxyl group at the oxazepine C-2 position will give the most balanced
compound in terms of potency and interspecies antifungal spectra.
The oximes (Figure 1.1.4.1)27b didn’t give any better derivatives in terms of in
vitro antifungal activity compared to the simple ether derivatives reported by Merck
(Figure 1.1.1.1), but the SAR study clearly confirmed the observation made by Merck that
the best activity was achieved when a 5 or 6 carbon aliphatic chain is attached (Figure
1.1.4.1, lower left).
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Figure 1.1.4.1: Sordarin Oxazepine Derivatives and Oxime Derivatives

Additionally, three types of sordarin derivatives were prepared by organometallic
additions to a fully protected sordaricin aldehyde.27d The alkyl alcohol and ketone
derivatives had not only lower potency but also higher cytotoxicity (cell type not specified).
With the propargylic alcohol and ketone derivatives, it is clear that the ketone derivatives
are more potent than the alcohol counterparts. Only 2 carbon-homologated sordaricin
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derivatives (Figure 1.1.4.2, bottom) were able to maintain good activity against C. albicans,
and compounds with bigger and more polar sidechains were poorly active.

Figure 1.1.4.2: Sordarin derivative prepared from sordaricin aldehyde
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One major success of BMS in this field was the identification of a broad-spectrum
azasordarin inspired by Glaxo’s azasordarin derivative GW513920 (Figure 1.1.4.3).27c By
shifting the methyl group from C-6’ to C-5’ on the morpholine ring, the compound started
to show activities against C. neoformans and A. fumigatus, which GW513920 was not able
to inhibit. Next, based on the observation that the metabolism process of this kind of
azasordrarin involves a N-dealkylation, they increased the bulk of the C-5’ substituent from
a methyl to an isopropyl or spirocyclopentyl group, leading to a reduction in the total
clearance from 95 mL/min/kg to 20 mL/min/kg.
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Figure 1.1.4.3: Broad-spectrum azasordarin with improved pharmacokinetic properties
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1.2 Total Synthesis of Sordarin

This section will mainly focus on the total synthesis work towards sordarin and its
congeners. The synthesis of sordarin analogs by Ciufolini et al.28 will be discussed together
with Diels-Alder reaction literature in chapter 2.
There are three sordarin total syntheses to date, systematically reviewed by
Liang.29 The first two total synthesis by Kato30 and Mander31 featured the same strategy
for the key step of constructing the tetracyclic sordaricin skeleton, namely an
intramolecular Diels-Alder reaction, while Narasaka32 later took a different approach by
featuring a Tsuji-Trost reaction. (Figure 1.2.1)
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Figure 1.2.1: Overview of approaches to the total synthesis of sordarin.
1.2.1

Kato’s Total Synthesis of Sordaricin Methyl Ester

Kato’s synthesis (Figure 1.2.1.1)30 commenced by condensing two chiral
synthons 1 and 2 via a Grignard-type carbonyl addition,33 the resulting alcohol was then
converted to methyl ether 3. A subsequent Cope rearrangement was smoothly conducted at
200 oC to give enol ether 4. Singlet-oxygen oxidation34 and AcCl-promoted rearrangement,
followed by deprotected with Pearlman’s catalyst and a selective syn-reduction of the nonconjugated alkene using iridium black furnished ester 5, the free alcohol of which was then
re-protected with TBSCl. The cyclopentene was further oxidized to cyclopentadiene 6 by
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MoO5-mediated α-hydroxylation following by dehydration condition using SOCl2. Next,
the cyclopentane was elaborated into the Diels-Alder dienophile 8 by TBS removal,
converting the resulting enol to TMS enol ether followed by a Saegusa oxidation. DielsAlder precursor 8 performed the key intramolecular DA reaction smoothly at 40 oC to give
the desired tetracycle 9. Kato did not proceed further to synthesize the fully elaborated
sordarin molecule (Figure 1.2.1.1).

Figure 1.2.1.1: Kato’s Total Synthesis of Sordaricin Methyl Ester

1.2.2

Mander’s Total Synthesis of Sordaricin
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Mander’s strategy in constructing the tetracyclic skeleton is very similar with
Kato’s synthesis described above. In that they both featured the intramolecular [4+2]
cycloaddition, although their strategy of preparing the precursor was different. Mander’s
synthesis (Figure 1.3.2.1)31 used enone (+)-10 and (-)-10 as the initial starting materials.
First, iodide 12 was prepared from (+)-10 through a 13 step synthesis, then (-)-10 was
converted to 11 by 1,4-addition of KCN. Alkylation was then performed using 11 and 12
to give a single diastereomer 13. The nitrile group of 13 was then reduced twice to give its
corresponding alcohol, which is in turn protected with MOM. Glycol protected ketone was
then released under acid condition to give 14. 14 underwent a retro-Diels-Alder reaction
smoothly at 180 oC giving enone 15. Acylation at the α-position of enone 15 was achieved
by enolization and addition to MeOC(O)CN. Then the resulting ketone was converted to
its corresponding enol triflate by using McMurry’s triflating reagent, followed by the
addition

of

the

higher

order

cuprate

derived

from

2-Th(Cu)CNLi35

and

isopropylmagnesium chloride. This furnished the cyclopentadiene moiety to give 16. Then
a double MOM deprotection and subsequent allylic oxidation furnished the Diels-Alder
reaction predursor 17. The key Diel-Alder reaction went smoothly at 40 oC to give the
desired tetracyclic skeleton (Figure 1.3.2.1).
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Figure 1.3.2.1: Mander’s Total Synthesis of Sordaricin
1.2.3

Narasaka’s Total Synthesis of Sordarin

Narasaka32 not only synthesized the tetracyclic skeleton using Tsuji-Trost reaction
rather than Diels-Alder cycloaddition, but they were also able to synthesize the novel sugar
unit in the original sordarin molecule and perform a β-selective glycosylation to finish the
first enantioselective synthesis of the complete sordarin molecule.
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Narasaka’s key step of constructing the sordarin tetracyclic skeleton featured a
Tsuji-Trost addition which called for the tricycle 6 as the precursor. Chiral enone 19 was
used as the initial starting material, which was first converted to bicyclo[5.3.0]decan-3-one
21 by subjecting the intermediate 20 to oxidative radical cyclization using a AgNO3(NH4)2S2O8-pyridine catalytic system.36 To construct the tricyclic system, they started with
a stereo- and regioselective allylation at C-3 of 22 using a hydrazine intermediate derived
from ketone 21. Olefin 22 was then subjected to oxidative cleavage to give the
corresponding aldehyde, which was then converted to a β-keto ester,37 which in turn
performed a Knoevenagel condensation to give 23. To furnish the Tsuji-Trost precursor 27,
from 23 two vinyl groups were introduced as equivalents of the hydroxy methyl and formyl
parts of sordaricin to give 26, finally ethoxy carbonylation of 26 and TBS deprotection
gave the Tsuji-Trost precursor 27. The key Tsuji-Trost addition was performed smoothly
in the presence of NaH giving only 5% of β-hydride elimination byproduct. The tetracyclic
compound thus generated was further elaborated to give sordarin ethyl ester 28.
With the sordaricin core in hand, they then focused on the β-selective
glycosylation of 28. After a model study, they concluded that by attaching a 4methoxybenzoyl group to the C-3 hydroxyl group of the carbohydrate unit,

1,3-

anchimeric assistance can be utilized to favor a β-selective glycosylation under
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Mukaiyama’s glycosylation conditions.38 Compound 29 was thus synthesized from Dmannose and coupled with 28 resulting a 6.5:1 β:α mixture, which was then deprotected
by DDQ. The β isomer was isolated and the 4-methoxybenzoyl protecting group removed
to give sordarin (30).
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Figure 1.3.3.1: Narasaka’s Total Synthesis of (-)-Sordarin

In conclusion, the total synthesis efforts described above all have more than 20
linear steps, and even very small changes in the final compound may require tremendous
changes in prior steps. In medicinal chemistry studies, functional groups and substituents
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of interest need to be switched quickly to establish SARs, and these approaches are
generally not amenable to such SAR studies.
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2.0 Research Proposal

2.1 Design of Novel Sordarin Derivatives

Based on previous medicinal chemistry studies on sordarin and its derivatives
(Chapter 1.2), a clear SAR map can be drawn (Figure 2.1.1). The glycosyl moiety of
sordarin is the most intensively studied part due to its ease of replacement. By far, Glaxo’s
"azasordarin" analogs represented by GW47155839 with their morpholino glycone are the
most potent analogs against C. albicans, with a MIC typically lower than 0.001 µg/mL
(Figure 1.1.2.1), and a C-5’ substituted version of the same kind of sordarin made by BMS
has the most balanced profile in terms of potency, PK, and antifungal spectrum40 (Figure
1.2.4.3).
The adjacent aldehyde and carboxylic acid groups on the norbornene core were
clearly essential both from Merck’s substitution study13 and the crystal structure published
by Andersen.15
There is currently no clear evidence whether the isopropyl group on the
norbornene core is essential or not. The C-6 and C-7 position on the cyclopentane ring was
proved to be the oxidation site when sordarin is subjected to P-450 metabolism19 (Figure
2.1.1), and thus substitution or replacement of the cyclopentane moiety with an inert group
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may slow down drug metabolism, resulting in a better pharmacokinetic (PK) profile.

Figure 2.1.1: SAR map of sordarin

The previous SAR studies discussed in the first chapter included some glycoside
replacements that are able to deliver compounds with very high potency against various
fungal species. Nonetheless, none of those candidates were advanced into clinical trials,
presumably because of poor PK profiles such as high clearance rate, and thus, the main
goal of this research is to identify a novel class of sordarin analogs that have improved PK
profiles while maintaining a high potency against various fungal species.
There are still very few reported SAR studies that focus on modifications of the
sordarin core bicycle. To substitute the P-450 oxidation site on C-6 and C-7 with an
oxidation-resistant replacement, a total synthetic strategy must be taken to construct the
core. In a semi-synthetic approach, such as those reported previously, it is difficult to
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modify the unfunctionalized cyclopentane moiety on the genuine sordarin core. A bicyclicsordarin analog is thus proposed (Figure 2.1.2).

Figure 2.1.2: Aryl/Alkyl bicyclic sordarin analogs

By deleting the six-membered ring on the western side of the norbornene core and
replacing the cyclopentane ring fused to it with an aryl or alkyl group, the synthetic route
can be largely shortened while still keeping the essential pharmacophoric groups in correct
positions. Most importantly, blocking the metabolically labile site of the molecule with a
fluorine would most likely make the molecule more inert to P-450 oxidation, and thus
improve the agent’s half-life and result in a lower clearance rate.
This approach is based on the concept of Function-Oriented Synthesis (FOS)
advocated by Wender.41 FOS focuses on reproducing the parent molecule’s (usually a
natural product) biological activity with simpler analogs, and thus, reducing the amount of
synthetic work required, and permitting better access to diverse analogs that may have
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improved properties. Multiple successful examples were reported using this strategy.
Selected examples are given below (Figure 2.1.3).
Based on pharmacophoric analysis, the anticancer agent bryostatin 1 was divided
into a spacer domain and a recognition domain. The spacer domain was then simplified to
contain an unsubstituted tetrahydropyran ring and a 1,3-dioxane ring. The recognition
domain was kept mostly intact. The resulting analog required only 29 synthetic steps
compared to 70 steps for the parent molecule. Additionally, it was able to show an improved
binding affinity with PKC (Equation (a), Figure 2.1.3).42
The FOS approach with the anticancer agent laulimalide highlights the ability
of this strategy to address stability issues. The epoxide at the C-16 position which is
responsible for a nucleophilic ring-opening that causes a dramatic loss of activity against
MDA-MB-435 cells was eliminated. The resulting analog, although not as potent as its
parent molecule, allowed for an investigation of the features of laulimalide that control its
activity (Equation (b), Figure 2.1.3).43
The FOS approach was applied briefly to sordarin as well. The monocyclic analog
316 reported by Glaxo19 retained only the minimum required pharmacophores. Despite the
fact that the rigidity of the analog was largely lost comparing to its parent molecule, it was
able to show weak activity against C. albicans (Equation (c), Figure 2.1.3).
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Figure 2.1.3: Examples of Function-Oriented Synthesis
2.2

Synthetic Route Proposals

To access a novel bicyclic sordarin scaffold such as 32 in Figure 2.1.2, a
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retrosynthetic analysis is outlined below (Figure 2.2.1). The glycosyl group can be easily
installed by conventional glycosylation or anomeric alkylation. The key step to construct
the C-2 quaternary center of the bicyclo[2.2.1]heptane core is envisaged to be achieved by
one of five different strategies (Figure 2.2.2). These strategies all require cyclopentenone
38 as a common intermediate. 38 can be prepared from unsaturated ester 39 by allylic
oxidation and silyl enolation. Ester 39 in turn, can be accessed by two different synthetic
routes, depending on what method is used to introduce the chiral center. One of these routes,
as described below, also provides an option for synthesis of racemic 38 and eventually
racemic 32 for a faster and cheaper validation of concept.
The five different strategies to furnish a quaternary chiral center at the C-2
position of 35 (Figure 2.2.1) is depicted in detail in Figure 2.2.2. These strategies can be
grouped into two general categories depending on whether the C-2 quaternary center is
formed at the same time as the formation of the bicyclo[2.2.1]heptane core, or afterwards.
Stereoselective Diels-Alder reaction and double Michael addition belong to the first
category (48, 49, 52, Figure 2.2.2). The C-2 quaternary center can also be formed after the
formation of the bicyclo[2.2.1]heptane core by trapping a C-2 carbocation with cyanide or
using a C-2 anion to conduct a SN2- or SNAr-type substitution (51, 52, Figure 2.2.2).
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Figure 2.2.1 Retrosynthetic analysis for bicyclic sordarin analog 32

The chiral center of 38 can be introduced by Trost asymmetric allylic alkylation
(AAA) reaction (Route A, Figure 2.2.1).44 Unsaturated ester 39 can be accessed by
applying Krapcho decarboxylation45 of diester/acid 42 followed by olefin isomerization.
42 is in turn made by RCM of diene 43. Chiral diene 43 can be made enantioselectively by
using Trost asymmetric allylic alkylation where vinyloxirane 45 and malonic ester 46 serve
as electrophile and nucleophile respectively.
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Figure 2.2.2 Proposed strategies for constructing the desired bicyclo[2.2.1]heptane core
with quaternary center at C-2. PG = protecting group.

Another route features palladium catalyzed carbonylation to give 39 (Route B,
Figure 2.2.1), which can access either chiral or racemic 41. For the chiral approach, a
chemoenzymatic resolution of 47 using Baker’s yeast46 or Amano PS47 will furnish the
chiral center of 41. Chemoenzymatic resolution is advantageous to use in early stage of the
synthesis for its lower cost and robustness. Optionally, the chiral center of 41 can be
introduced by direct asymmetric α-hydroxymethylation such as examples reported by
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Mlynarski,48 but the cost will be higher compare to chemoenzymatic resolution for its
relatively high catalyst load (10 mol%) and commercially unavailable ligand. For a racemic
approach, rac-41 can simply be made from cyclopentanone and formaldehyde via aldol
reaction.

2.2.1

Cyclopentanone and Cyclopentadiene Synthesis

Two different routes used to synthesize the common intermediates 37 and 38 are
described in this chapter.
2.2.1.1 Trost Asymmetric Allylic Alkylation Route
(Route A)
To build a chiral primary alcohol that has a quaternary center at its C-2 position,
the application of asymmetric allylic alkylation (AAA) developed by Trost44 was chosen
in this first proposed route (Figure 2.2.1.1.1). Methyl malonate under Trost AAA
conditions could asymmetrically add to vinyloxirane 45 to generate a chiral quaternary
center and a primary alcohol, which could then be protected with TBS. The malonic
position is deprotonated by NaH and allylated to give compound 53. 53 will then be
subjected to Krapcho decarboxylation resulting in diene 54, which after ring closing
metathesis and tandem olefin isomerization will give α,β-unsaturated ester 55. From 55,
allylic oxidation, such as under the conditions developed by Corey,49 will be used to oxidize
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the C-3 position to a ketone. This ketone is then converted into silyl enol ether 57, which
is the cyclopentadiene needed for the key Diels-Alder reaction. (Figure 2.2.1.1.1)
There are, however, some disadvantages for this route. The Trost AAA reaction
requires use of the expensive Trost ligand. From a synthetic point of view, this may not be
ideal for large scale synthesis. More importantly is that the final cyclopentadiene product
57 intrinsically has to bear a methyl group at C-5 position for this type of Trost AAA
reaction doesn’t tolerate 2-vinyloxirane as an electrophile. If the stereochemical outcome
of the key bicyclo[2.2.1]heptane core forming step is proven to give the undesired
diastereomer at C-2 position, then to eliminate the steric effect of the C-5 methyl group of
57, a 5-demethyled analog of 57 would be required, which cannot be easily made through
this route (see discussion in chapter 3).

Figure 2.2.1.1.1: Proposed Trost asymmetric allylic alkylation route to cyclopentadiene
57
2.2.1.2 Palladium-Catalyzed

Carbonylation

Route
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(Route B)
In order to improve the Trost AAA route in terms of cost, and also prepare for the
potential need of a 4-monosubstituted cyclopentenone 38 (R1 = H), two chemoenzymatic
routes were proposed.
First, to synthesized the 4-monosubstituted cyclopentanone 63, racemic βketoester 47 will be subjected to Baker’s yeast asymmetric reduction. Baker’s yeast is
known to be able to catalyze the reduction of (R)-47 much more faster than its enantiomer
to give (1R, 2S)-2-hydroxycyclopentanecarboxylate (59).46 The desired (S)-47 will remain
intact while the ketone of (R)-47 will be reduced to alcohol 59. (S)-47 will then be reduced
to diol whose primary alcohol is selectively protected with TBDPS, then a Dess-Martin
oxidation50 will furnish chiral ketone 60. 60 will then be converted into enol triflate 61
using McMurry’s triflating reagent.51 61 will then be homologated into α,β-unsaturated
ester 62 by Pd-catalyzed carbonylation. Allylic oxidation conditions, such as those
developed by Corey,49 will be used to oxidize the C-3 position of 62 to α, β-unsaturated
ketone 63. Finally 63 can be converted into an enol ether such as 64, if a Diels-Alder
reaction is used for the construction of the bicyclo[2.2.1]heptane core (Figure 2.2.1.2.1).
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Figure 2.2.1.2.1: Baker’s yeast route to chiral cyclopentadiene 64

Enzymatic transesterification using a suitable lipase provides a way of
synthesizing 4-disubstituted cyclopentenone 69 (Figure 2.2.1.2.2). Starting from the same
starting material, racemic β-ketoester 47 will be methylated at the α-position. After
protecting its ketone as a ketal, the ester is reduced to the primary alcohol, followed by
hydrolysis of the ketal, generating racemic alcohol 65. 65 is then subjected to enzymatic
transesterification where the (R)-65 will be able to perform the transesterification much
faster with vinyl acetate giving highly enantioenriched ketone 66.47 From 66, the
subsequent steps will be the same as described above in the Baker’s yeast approach, giving
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access to a 4-disubstituted cyclopentennone such as 69 (Figure 2.2.1.2.2).

Figure 2.2.1.2.2: Amano lipase route to chiral cyclopentadiene 70

In addition, a cheaper and faster synthesis of the racemic building block
cyclopentenone 74 and cyclopentadiene 75 can be achieved by preparing racemic ketone
71 from cyclopentanone via aldol reaction with formaldehyde. The process after 71 will be
the same as described above in the chiral approach (Figure 2.2.1.2.3).
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Figure 2.2.1.2.3: Aldol route to racemic cyclopentadiene 75
2.2.2

Construction of Quaternary
Bicyclo[2.2.1]heptane core

Center

at

C-2

of

2.2.2.1 Diels-Alder Reaction using Functionalized
Cyclopentadiene
and
1,1-Disubstituted
Dienophile
The Diels–Alder reaction is a [4+2] cycloaddition between a conjugated diene and
an alkene, commonly termed the dienophile, to form a cyclohexene system. It was
discovered in 1928 by Otto Diels and Kurt Alder,52 and its application in total synthesis can
be backdated to Woodward's landmark 1952 syntheses of the steroids cortisone and
cholesterol.53
In the Diels-Alder reaction approach to our desired bicyclo[2.2.1]heptane core,
the diastereoselectivity (endo/exo) is anticipated to be the most challenging part. Since
prior SAR and crystallographic studies suggest that the carboxylic acid and its adjacent
aldehyde/nitrile group must maintain a specific orientation for compounds to be active
(Figure 2.1.1), this means that in our strategy the endo diastereomer is required and the
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Diels-Alder reaction should be endo-selective so that these two pharmacophores can be
placed in the same relative orientation as in sordarin. Uncertainty remains at this stage
about the stereoselectivity when a cyclopentadiene such as 76b is paired with 77 (Figure
2.2.2.2). Especially when R3 = Ar, due to the steric hindrance caused by the aryl group on
77, it is anticipated that the aryl group may be forced to the undesired endo position when
two substituents are present on the bridge proximal to the dienophile carbons.

Figure 2.2.2.1: Steric effect of 1,1-disubstituted dienophile with phenyl substituent.

However, there are some evidences that a phenyl substituent on the dienophile
might actually benefit endo-selective Diels-Alder reaction. In a review summarized by
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Hill,54 it was evident that as the size of substituent on the dienophile α-position increases,
the percentage of endo adducts decreases. But phenyl substituent in this context is an
exception, giving better endo-selectivity compared to α-methylacrylic acid (eq. (a) Figure
2.2.2.1). Davies55 reported a Lewis acid catalyzed Diels-Alder reaction using similar
dienophile. In his case, the endo-selectivity was further improved (eq. (b), Figure 2.2.2.1).
It should be remembered though, in these examples there are no significant steric bulk on
the diene side.

Figure 2.2.2.2: Steric effect caused by aryl group on the dienophile

To circumvent this issue, as described above in chapter 2.2.1.2, cyclopentadiene
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76a without a methyl group at its C-5 will be synthesized. There is however, another
potential issue if a 5-monoalkylated cyclopentadiene is used in a Diels-Alder reaction,
namely an undesired [1,5]-sigmatropic shift (usually hydride), which leads to a more
substituted diene.56 (Figure 2.2.2.3)

Figure 2.2.2.3: [1,5]-sigmatropic shift

These [1,5]-sigmatropic shifts can in some cases be minimized by handling the
cyclopentadienes at low temperatures. One milestone synthesis using a Diels-Alder
reaction with such a cyclopentadiene was reported by Corey,57 in which a copper catalyst
was used to accelerate the reaction at 0 oC without observing an appreciable amount of
cycloadduct generated from the isomerized 2-substituted cyclopentadiene.57 (Figure
2.2.2.4)
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Figure 2.2.2.4: Corey’s DA reaction used in the synthesis of prostaglandins

The half-life of 5-monoalkylated cyclopentadiene shown above is short at room
temperature, measured at 1.2 h for 5-methylcyclopentadiene.58 Gleason has reported that a
cyclopentadiene with an electron-donating 2-silyloxy group has greatly increased stability
towards isomerization (Figure 2.2.2.5).59 Also noteworthy is that in the same work,
Gleason conducted a Diels-Alder reaction using this cyclopentadiene with a 1,1disubstituted dienophile with and without a mild Lewis acid. In both cases the exo-product
dominated, which is consistent with the example shown in Figure 2.2.2.1 eq. (a).
Nonetheless, when a Lewis acid is present the amount of endo product is increased slightly
(Figure 2.2.2.5).
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Figure 2.2.2.5: Expanded half-life of Gleason’s diene and its Diels-Alder reaction
example

At the same time, if a substrate like 76a-b turns out to favor the undesired exo
adduct, as a backup plan, α,β-unsaturated N-acyloxazolidinones developed by Narasaka60
such as 80 can be used to increase the activity and endo selectivity by its steric effect and/or
its ability to chelate a Lewis acid, with the increased electron deficiency correlated with
increased endo selectivity61 (Figure 2.2.2.2).
A close example of a 5,5-dialkylated cyclopentadiene performing a DA reaction
with dienophile disubstituted with electron-withdrawing groups at C-1 was reported by
Ciufolini,28 in an effort to synthesize sordarin analogs by both inter- and intramolecular
Diels-Alder reactions (Figure 2.2.2.6). An analog of Danishefsky’s diene was used in their
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intermolecular Diels-Alder reaction, where cyclopentadiene 89 substituted by electron
donating groups at C-1 and C-3 is paired with dienophile 83. This reaction went smoothly
at 60 oC to give desired adduct 90. Interestingly, when they tried to introduce an alkyl group
at C-2 on the cyclopentadiene, even a methyl group could prevent the Diels-Alder reaction
from taking place. They attributed this failure to the adjacent bulky TIPS group (Figure
2.2.2.6).

Figure 2.2.2.6: Ciufolini’s intermolecular DA examples

In Ciufolini’s intramolecular DA reaction examples, there are great similarities
with the diene and dienophile proposed in this research. Compound 95 has a silyloxy diene,
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which is proven in his example to be able to increase the diene’s HOMO energy level and
enabled a Diels-Alder reaction that was otherwise inert (Figure 2.2.2.7).

Figure 2.2.2.7: Ciufolini’s intramolecular DA examples

Other than the conventional type of Diels-Alder approach described above, an
organocatalytic asymmetric Diels-Alder reaction62 could also provide a promising path to
the desired bicyclo[2.2.1]heptane core. An example of such a Diels-Alder reaction reported
by Jørgensen is depicted in Figure 2.2.2.8.63 This strategy uses a quinidine-derived amine
catalyst 98 to form an intermediate dienamine from cyclopentenone. In the transition state,
the tertiary ammonium directs and activates a dienophile by acting as a hydrogen bond
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donor (eq. (a), Figure 2.2.2.8). This method can give high diastereo- and
enantioselectivities and doesn’t need a separate step to convert the cyclopentenone to a
diene. A cyclopentenone such as 100 could be used to examine this approach (eq. (b),
Figure 2.2.2.8).

Figure 2.2.2.8: Jørgensen’s organocatalytic asymmetric Diels-Alder reaction

In conclusion, to construct the bicyclo[2.2.1]heptane core with an endo-selective
Diels-Alder reaction, two general approaches could be taken. For a conventional
intermolecular Diels-Alder reaction, using a Lewis acid with or without the N-
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acyoxazolidinone decorated dienophile could be a useful method if a thermal Diels-Alder
reaction leads to an undesired exo-adduct. If a 5-monosubstituted cyclopentadiene is to be
used, undesired [1,5]-sigmatropic shifts could can be prevented by increasing the electron
density on the cyclopentadiene with silyloxy substitution or handling the cyclopentadiene
at lower temperature in the presence of a Lewis acid catalyst. For an organocatalytic DielsAlder approach, the cyclopentenone precursor 100 can be used directly to examine its
validity.

2.2.2.2 Double Michael Addition

Yamada64 has reported a double Michael addition to construct a similar
bicyclo[2.2.1]heptane skeleton using a 3-alkoxyl cyclopentanone 102 together with a chiral
Michael acceptor 103 (eq. (a), Figure 2.2.2.2.1). This addition afforded in high yield the
bicyclo[2.2.1]heptane scaffolds 104a-b, with the high stereoselectivity induced by the
chirality of 103.
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Figure 2.2.2.2.1: Yamada’s double Michael example and proposal to construct scaffold
103

If the C-2 diastereochemistry turns out to be undesirable with the Diels-Alder
approach described in chapter 2.2.2.1, the double Michael strategy will be a good
alternative to reach scaffold 103 (eq. (b), Figure 2.2.2.2.1).

2.2.2.3 SNAr/SN2 using C-2 Anion

As described in section 2.2, the C-2 quaternary center of the bicyclo[2.2.1]heptane
core can also be furnished using a C-2 anion to conduct SNAr- or SN2-type substitution
reactions. This approach is based on the examples reported by Caron, in which he reported
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that 2-cyano-5-norbornene 105 can undergo SNAr with aryl fluorides exclusively from the
exo face to furnish a tertiary nitrile at the C-2 position of the skeleton (eq. (a), Figure
2.2.2.3.1).65 This stereoselectivity was also seen in a SN2 reaction using the same starting
material with BnBr, and the C-2 anion attacked the electrophile exclusively from the exo
face to give 107.
To take this approach, the silyloxy diene 108 described in previous chapters can
be paired with acrylonitrile to simply form a diastereomeric mixture of secondary nitriles
at C-2 to give scaffold 109. 109 can then be subjected to the same conditions reported by
Caron to furnish the C-2 quaternary center of 110 (eq. (b), Figure 2.2.2.3.1).
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Figure 2.2.2.3.1: SNAr/SN2 using C-2 anion of bicyclo[2.2.1]heptane scaffold
2.2.2.4 Nucleophilic Trapping of C-2 Cation

In the case of an aryl tertiary nitrile, the C-2 tertiary center may also be furnished
via a nucleophilic trapping of a stabilized C-2 cation. As shown in equation (a) in Figure
2.2.2.4.1, Yanagisawa66 showed that in a monocyclic system, a tertiary benzylic
carbocation can be trapped with a cyanide source such as TMSCN to give aryl tertiary
nitriles 112. There is a clear trend in these examples that cations stabilized by a more
electron-donating aryl group give higher yields. There are also some examples of
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nucleophilic trapping of this type of carbocation on a bicyclic system, one pertinent
example reported by Lattanzi67 where a camphor derived C-2 cation was successfully
trapped with hydroperoxide (eq. (b), Figure 2.2.2.4.1). However, this method is also highly
dependent on the substituent used to stabilize the cation. If a phenyl substituent is used
instead of a furan-2-yl group to stabilize the cation, the trapping was unsuccessful. Instead,
it leads to dehydration and Wagner–Meerwein rearrangement to give olefins 121 and 122
respectively (eq. (c), Figure 2.2.2.4.1). Therefore, the validity of this strategy should be
examined in a model system using substrates easily derived from camphor before an
approach depicted in equation (d) can be tested.
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Figure 2.2.2.4.1: Nucleophilic trapping of stabilized carbocation
2.2.3

Glycosidation and Late-stage Modifications

The initial goal of this research is to synthesize a series of analogs with different
R2 groups at the C-2 exo position. Since the glycosyl moiety SAR has already been studied
extensively (Chapter 1), once the desired sordaricin cores 127 or 134 are synthesized, they
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will be coupled with selected glycoside replacements to give 124, 125, 126 (Figure 2.2.3.1).
124 and 126 were proposed because their known analogs 12068 and 12140 possess high
potency, and the glycones are relatively easy to access. The glycone in 126 has shown both
high potency and broad antifungal spectrum in sordarin derivatives, and thus, it is the most
favorable glycone to use at this stage. All different R2 variants will be tested with this
glycoside first.

Figure 2.2.3.1: Target compounds with selected glycoside replacement
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The synthesis of glycone 140 starts from cyclopentanone (Figure 2.2.3.2). Imine
formation with ammonia followed by addition of cyanide gives aminonitrile 135. 135 will
then be hydrolyzed to acid 136. Reduction by LiAlH4 will give known amino alcohol 137,69
which by reductive amination with 2,2-dimethoxyacetaldehyde, gives amino alcohol 138.
The 2-chloroallyl group will then be installed by SN2 to the secondary amine giving 139.
Finally, the protected aldehyde is released to give glycone 140. The formation of glycone
142 will follow the method reported by Brands70 by condensing amino alcohol 141 with
glyoxylic acid (Figure 2.2.3.2).

Figure 2.2.3.2: Proposed synthesis of selected glycosides

The glycosidation of the bicyclo[2.2.1]heptane core to give either nitrile 130 or
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aldehyde 133 can start from alcohol 127 or 134 (Figure 2.2.3.3). Since the nitrile 127 may
be synthetically more accessible than its aldehyde analog, the final compound 130 can
potentially be reduced to its aldehyde counterpart 133. Core structure 127 will be
synthesized with highest priority.

Figure 2.2.3.3: Glycosidation and protecting group manipulation

The desired bicyclo[2.2.1]heptane cores 143 and 144 can also be subjected to
various late-stage modifications for SAR studies, especially at the C-5 and C-6 position of
the bicyclo[2.2.1]heptane core which has never been explored before. Some proposed
modifications are given in Figure 2.2.3.4.
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Figure 2.2.3.4: Late-stage modification on bicyclo[2.2.1]heptane core
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3.0 Results and Discussion

Much of the work described in this chapter has been published in Tetrahedron
Lett., ChemRxiv preprint,71 and J. Org. Chem.72 This chapter describes the experimental
results in pursuing the synthetic proposal discussed in Chapter 2.2

3.1 Cyclopentanone and Cyclopentadiene Synthesis

Two routes featuring Trost AAA reaction and Pd-catalyzed carbonylation
respectively to reach cyclopentenone 38 (Figure 2.2.1) are described in this chapter.

3.1.1

Trost Asymmetric Allylic Alkylation Route

This route started with a Trost AAA reaction using 2-methyl-2-vinyloxirane and
dimethyl malonate. The desired alcohol 203 however, was not observed (Figure 3.1.1.2).
Instead, lactone 204 was formed through lactonization. At this early stage, four different
nucleophiles 350-353 were tested to examine if the lactonization could be avoided, but they
either did not react or they still give a lactone product such as 230 or amino enol ether 234
(Figure 3.1.1.1).
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Figure 3.1.1.1: Vinyloxirane with various nucleophiles in Trost AAA reaction

The lactone product 204 was thus used as is. An α-allylation of 204 furnished
racemic diene 205 in excellent yield, which was then subjected to ring-closing metathesis.
Due to the fact that the lactone ring restricted the orientation of the substitutents on the two
adjacent quaternary centers, only the diastereomer of 205 that had the two olefins syn to
each other reacted to give bicyclic lactone 206. The stereochemistry was assigned based
on a bicyclic ketone stability study by Hudlicky,73 which suggested in a cis- and trans-fused
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bicyclic ketone equilibrium, the cis-fused bicyclic ketone dominated. Then, a Krapcho
decarboxylation proceeded smoothly to give the lactone 207. Initial attempts to isomerize
the double bond to give an α,β-unsaturated lactone 229 by ruthenium hydride generated
from Grubbs ruthenium carbene and MeOH74 were not successful.

Figure 3.1.1.2: Trost AAA route to cyclopentadiene 236
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Alternatively, to avoid the issue that only one diastereomer of 205 is reactive in
the RCM reaction, the lactone ring can be opened prior to the RCM step. Therefore, 205
was decarboxylated to give 208. Then, 208 was be converted to 209 by an alkylative ring
opening with hydroxide and benzyl bromide.75 As expected, 209 gave a complete RCM
conversion to 210. A tandem alkene isomerization of 210 to α, β-unsaturated ester 211 by
switching the RCM solvent from DCM to MeOH and applying heat was attempted.
However, the vast majority of 210 remained intact and 10% of an unexpected
transesterification product 212 was obtained after prolonged heating. Grubbs’ catalyst is
known to catalyze alkene isomerizations after RCM reactions,76 especially when the newly
generated alkene is at the β position to a heteroatom. However, in this case, the Grubbs’
catalyst does not appear to be able to shift an alkene two bonds away to give a more
conjugated structure. A ruthenium catalyst capable of doing long range alkene
isomerization77 has also been taken into consideration. It appears that this type of catalyst
works best when converting an alcohol that has a remote alkene to an aldehyde or ketone.
There was no reported example in which a remote alkene is shifted to give an α,βunsaturated ester. Moreover, this type of catalyst usually bears a highly sophisticated ligand
that is not trivial to synthesize. Therefore, the isomerization effort to reach 211 and this
route were not pursued further.
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3.1.2

Routes
Containing
Reactions

Pd-Catalyzed

Carbonylation

3.1.2.1 Lipase-Catalyzed Transesterification Route

α-Alkyl-α-hydroxymethylcycloalkanones such as 238 can undergo a lipasecatalyzed kinetic resolution reaction where the (R)-enantiomer of racemic 238 undergoes
a transesterification with vinyl acetate faster than its enantiomer, to give the known chiral
compound 239 (Figure 3.1.2.1.1).47 Acetate 239 was smoothly synthesized from 238.
However, this route was discontinued due to the concern that a 5,5-disubstituted
cyclopentadiene might be problematic in introducing bulky substituents (such as aryl) at
the exo position of desired bicyclic intermediates. (see Section 2.2.2).
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Figure 3.1.2.1.1: Lipase-catalyzed transesterification route
3.1.2.2 Baker’s Yeast Reduction Route

In the original synthetic plan discussed in chapter 2.2.1.2, Baker’s yeast reduction
of rac-237 was expected to give chiral alcohol 244 and the unreacted (S)-237. However,
despite the fact that this reaction appeared to be a kinetic resolution, the assumption that
(S)-enantiomer of 237 would remain intact in this reaction appeared to be invalid. after the
reaction was complete, the crude NMR only showed the existence of 244 without any
isolated rac-237 or (S)-237. We speculate that (S)-237 may have been hydrolyzed by the
yeast esterases.
Nonetheless, compound 224 can be used as an enantiomeric starting material to
validate the synthetic route to the desired cyclopentadiene. 224 was reduced to the diol,
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and the primary alcohol was protected as a TBDPS ether. Next, the intermediate secondary
alcohol was oxidized to ketone 245 using DMP, which was then deprotonated by LDA and
converted to enol triflate 248 in 21% yield. This is likely due to the low reactivity of
McMurry’s triflating reagent at low temperature.78 The Pd-catalyzed carboxylation went
smoothly to give α,β-unsaturated ester 249, which in turn gives a smooth conversion to
ketone 250 under allylic oxidation conditions reported by Corey.49 (Figure 3.1.2.2.1)
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Figure 3.1.2.2.1: Baker’s yeast reduction route
3.1.2.3 Racemic Aldol Route

Although an enantioselective synthesis to the desired cyclopentadiene 247 is also
possible through an enantioselective aldol reaction between cyclopentanone and
formaldehyde to give 246, to quickly examine the key Diels-Alder reaction, a racemic
synthesis of the racemic diene 258 was conducted (Figure 3.1.2.3.1). The synthesis started
with an aldol reaction of cyclopentanone with formaldehyde to provide a primary alcohol,
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which is then protected with TBDPS to give ketone 252. 252 was treated with McMurry’s
triflating reagent to give enol triflate 253. This triflating reaction gave the best result using
NaHMDS, other bases such as LDA resulted in a very sluggish reaction. Pd catalyzed
carbonylation converts 253 to α, β-unsaturated ester 254. Allylic oxidation of 254 provided
cyclopentenone 255. Attempts were made to convert 255 into diene 259 using TBSOTf and
TEA. However, based on crude NMR, the electron-withdrawing methyl ester seemed to
have caused the desired diene to be extremely prone to isomerization, leading to the loss
of its stereocenter. Diene 259 could not be trapped in Diels-Alder reactions with an excess
of highly active dienophiles such as maleic anhydride and dimethyl acetylenedicarboxylate,
presumably due to its low HOMO level. To circumvent this issue, 255 was then reduced to
its corresponding diol, the primary alcohol of which was selectively protected with acetate
to give 256 as a mixture of diastereomers. PCC oxidation of the secondary allylic alcohol
furnished α, β-unsaturated ketone 257, which reacted smoothly give the much more stable
silyloxy diene 258 when subjected to TBSOTf and TEA. Given its acid sensitivity, 258 was
not purified before being used in a Diels-Alder reaction. (Figure 3.1.2.3.1)
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Figure 3.1.2.3.1: Racemic route to silyloxy diene 258
3.2 Construction

of

Quaternary

Center

at

C-2

of

the

Bicyclo[2.2.1]heptane Core
This chapter describes the experimental results in pursuing the synthetic proposal
discussed in chapter 2.2.2.

3.2.1

Diels-Alder Reaction
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3.2.1.1 Model Reaction

A model reaction is designed to assess the validity and stereoselectivity of a DielsAlder reaction using 5,5-disubstituted cyclopentadiene with l,l-disubstituted ethylenes
(Figure 3.2.1.1.1).

Figure 3.2.1.1.1: Model DA reactions

A simplified 5,5-disubstituted cyclopentadiene 262 can be easily synthesized from
isobutyraldehyde using a protocol reported by Hudlicky in Organic Syntheses (Figure
3.2.1.1.1).79 The DA reaction outcomes of the more electron-rich diene 262 with dienophile
260 or 261 were used to decide which diene (e.g. 243 or 258) should be the first priority
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for the desired endo-selective Diels-Alder reactions.
The key Diels-Alder reaction was examined using the model molecule
cyclopentadiene 262. 262 was paired with dienophile 270 and 267, which may be used in
synthesizing desired drug candidates. When paired with 267, even prolonged heating in a
sealed tube at 140 oC was not able to deliver any desired DA products (Figure 3.2.1.1.2).
When Lewis acids such as BF3-OEt2 or AlCl3 were used, diene 262, a silylenol ether,
hydrolyzes to the α, β-unsaturated ketone. However, reaction with dienophile 270 gave a
complex mixture when a strong Lewis acid such as TiCl4 was used. The structure of this
byproduct has yet to be determined but may be a Michael addition product between 262
and 270.
Since diene 262 and dienophile 270 had never been reported together in a DA
reaction, they were paired with commonly used dienophiles and dienes respectively to
ensure that they were capable of doing a normal DA reaction. 262 was paired with maleic
anhydride, and the reaction went smoothly at rt to give DA product 269. 270 was paired
with cyclopentadiene, and under conditions reported by Evans,80 it gave a single
diastereomer of the desired DA product 271. This product is assumed to be endo based on
the Alder Endo rule, since it is unlikely to give the exo product exclusively (Figure
3.2.1.1.2).
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This series of observations using the model diene 262 suggested that a Diels-Alder
reaction using 5,5-disubstituted cyclopentadiene with l,l-disubstituted alkenes is likely to
be difficult, although elimination of steric bulk from either side of the pair will make the
reaction feasible. Therefore, cyclopentadiene 258 was prioritized for synthesis.

Figure 3.2.1.1.2: Diels-Alder model reaction
3.2.1.2 Diels-Alder

Reaction using Functionalized
Cyclopentadiene
and
1,1-Disubstituted
Dienophile
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Initially the most desirable target compounds possess a fluorinated aryl group at
C-2 exo position (32, Figure 2.1.2), which we hypothesize should fit into the lipophilic
portion of the eEF2 binding pocket occupied by the cyclopentane ring of sordarin. The
installation of such aryl substituents has proven to be challenging. The initial attempt used
the 2-aryl-acrylaldehyde 274, but instead of the desired adduct 275, the unexpected
dihydropyran 276 was obtained (Figure 3.2.1.2.1). This product could be generated from
either a retro-Claisen rearrangement of 275 or an inverse electron demand, hetero Diels–
Alder reaction. Davies has published a comprehensive study on a similar system,55
although there appears to be no reported example of this rearrangement/DAINV with a silyl
enol ether. One notable difference in this case comparing with Davies’ study is that the
dihydropyran was the only product observed. The ratio of the DA adduct and its rearranged
product are known to be determined by extent of ring strain and extent of conjugation to
the involved carbonyl.81 In this case, an electron rich silyl enol ether and the electronwithdrawing aryl group may both contribute to this outcome. Silyl ketal 276 is an unstable
species that decomposed to racemic aldehyde 277 upon treatment with formic acid in
methanol, or sitting in the freezer for a month dissolved in DCM under neutral conditions.
The most straightforward way to circumvent the undesired hetero Diels-Alder reaction
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appeared to be using the nitrile or ester counterparts of 274, but unfortunately these
dienophiles failed to give any Diels-Alder adducts with 258.

Figure 3.2.1.2.1: Diels-Alder reaction using 258 and 274

To potentially circumvent the lack of Diels-Alder reactivity of acrylates, α,βunsaturated ester 278 with a more highly activating trifluoromethyl methyl group to
decrease the LUMO level of the dienophile. The trifluoromethyl group is also a desirable
substituent for our medicinal chemistry studies due to its lipophilic but metabolically stable
profile. After extensive screening of different solvents and Lewis acids, we learned that
diene 258 was indeed not compatible with most Lewis or Brønsted acids (e.g.
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trifluoroethanol, Table 3.2.1.2.1, entry 15), as reported by Gleason for a related OTBSsubstituted cyclopentadiene.82 Lewis acids that were compatible with 258 (Mg(OTf)2,
Mg(ClO4)2, and Eu(hfc)3; entries 4, 18 and 19) did not give any endo selectivity. The
diastereomers were tentatively assigned based on a report by Ishihara characterizing
endo/exo isomers with the same dienophile.83 The diastereoselectivity can be tilted slightly
by using different solvents; the highest exo selectivity was achieved in DCM (Table
3.2.1.2.1, entries 8, 9), and the most endo selective reaction was in hexanes (Table 3.2.1.2.1,
entry 11). Due to the low tolerance of 258 to Lewis acids, alternative dienophile/Lewis acid
combinations were not pursued to increase the proportion of the desired endo cycloadducts,
though it was anticipated that bulkier substituents than CF3 may favor the desired endo
cycloadducts.
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Lewis

Endo

e

/Exo

b

–78 to rt

InCl3

N/A

decomp.

DCM

–78 to rt

ZnBr2

N/A

decomp.

3

DCM

–78 to rt

Yb(OTf)3

N/A

decomp.

4

DCM

–78 to rt

Mg(OTf)2

0.75

68%

5

DCM

–78 to rt

Zn(OTf)2

N/A

decomp.

6

DCM

–78 to rt

Eu(OTf)3

N/A

decomp.

7

DCM

–78 to rt

K-10

N/A

decomp.

8

DCM

–78 to rt

–

0.67

83%

d

Entry

Solvent

Temp. (ºC)

1

DCM

2

Acid

Yieldc

9

DCM

rt

–

0.71

40%d

10

THF

rt

–

0.82

85%

11

hexanes

rt

–

1.04

96%

12

MeCN

rt

–

0.85

91%

13

acetone

rt

–

0.8

63%

14

MeOH

rt

–

0.93

86%

15

F3CCH2OH

rt

–

N/A

decomp.

16

PhCF3

rt

–

0.83

100%

17

EtOAc

rt

–

0.78

74%

18

MeCN

rt

Mg(ClO4)2

0.87

98%

19

CDCl3

rt

Eu(hfc)3

0.62

trace

a

Diene was washed with phosphate buffer (pH 7) before using; all experiments were run
for 24 h. bDiastereomers were assigned based on a previously reported analog,83 and the
ratio was determined with 19F NMR. cNMR yield using pentachloroethane as internal
standard, unless otherwise specified. dIsolated yield. e1 eq. except for entry 18 (0.9 eq.) and
entry 19 (0.2 eq.). decomp. = diene decomposed to 257. K-10 = Montmorillonite K-10.
Eu(hfc)3 = europium tris[3-(heptafluoropropylhydroxymethylene)-(+)-camphorate]. rt =
room temperature (22–23 ºC).
Table 3.2.1.2.1. Solvent and Lewis acid screening for Diels-Alder using 278
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In order to achieve an endo-selective Diels-Alder reaction and avoid the acid
sensitivity of diene 258, the organocatalytic asymmetric Diels-Alder reaction reported by
Jørgensen63 was examined. Using quinidine-derived amine catalyst 281, this catalyst
worked smoothly with 4-unsubstituted cyclopentenone (Table 3.2.1.2.2, entry 1), as was
reported. However, the scope couldn’t be extended to include the 4-substituted
cyclopentenone (Table 3.2.1.2.2, entry 2, 3). When the C-4 position of the cyclopentenone
is disubstituted, the reaction didn’t proceed (entry 2), likely because the transition state is
disrupted by the steric repulsion between the dienamine intermediate and the dienophile.
When the C-4 position is monosubstituted, the dienamine intermediate rearranged to cause
the loss of the stereogenic center at C-4 of enone 257 (entry 3), and no cycloaddition
products were observed.
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a

Entry

Enone

1
2
3

280
266
257

T/t

Result

60 ºC, 3d
60 ºC 3d; 100 ºC, 24h
60 ºC, 2d

100% conversion to 282aa
N.R.a
Decomposed 257b

Determined by GC-MS, b Determined by 1H NMR.
Table 3.2.1.2.2: Organocatalytic Diels-Alder reaction using 281
3.2.2

Double Michael Addition

Inspired by Yamada's reports of stereoselective sequential Michael reactions using
enolates generated from 3-alkoxy-cyclopentenones to generate [2.2.1] bicyclic adducts
(Figure 3.2.2.1),64 an analogous reaction starting from enone 257 and model enone 266.
These were treated with LDA to give their corresponding lithium enolates, followed by the
addition of an initial Michael acceptor. However, all enolates were unreactive in the
presence of several Michael acceptors under a number of different conditions (Table
3.2.2.1). Despite the fact that the cyclopentanone can be smoothly deprotonated (entry 8),
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use of Michael acceptors with different reactivities ranging from methyl 2-(4fluorophenyl)acrylate to acrylonitrile did not result in any difference. The addition of
HMPA (entries 2, 15, 11, 13) or heating (Entry 10–13) were not able to initiate this reaction
as well. Upon work up, the cyclopentenones 257, 266 were recovered. This inactivity could
be explained by the lack of an electron-donating alkoxy group at C3 of 257, 266. In the
case of 266, the methyl group at C-4 proximal to the approaching Michael acceptor likely
prevented its reaction due to steric hindrance (entries 9–11).

Figure 3.2.2.1 Sequential Michael reaction reported by Yamada64
Table 3.2.2.1 Attempted double Michael addition

Entry enone
1

257

Michael acceptorb

conditionsa

additive

resultc

R1= 4-FPh, R2= CO2Me

A

None

N.R.
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2

257

R1= 4-FPh, R2= CO2Me

A

HMPA (1 eq.)

N.R.

3

257

R1= 4-FPh, R2= CO2Me

A

None

N.R.

4

257

R1= CF3, R2= CO2Me

A

None

N.R.

5

257

R1= CF3, R2= CO2Me

A

HMPA (1 eq.)

N.R.

6

257

R1= CF3, R2= CO2Me

A

None

N.R.

7

257

acrolein

A

None

N.R.

8

257

none, quenched with D2O

A

None

deut.d

9

257

R1= H, R2= CO2Et

A

None

N.R.

10

257

R1= 4-FPh, R2= CO2Me

B

None

N.R.

11

257

R1= 4-FPh, R2= CO2Me

B

HMPA (1 eq.)

N.R.

12

257

R1= CF3, R2= CO2Me

B

None

N.R.

13

257

R1= CF3, R2= CO2Me

B

HMPA (1 eq.)

N.R.

14

266

R1= H, R2= CO2Et

A

None

N.R.

15

266

acrylonitrile

A

None

N.R.

16

266

R1= 4-FPh, R2= CO2Me

A

None

N.R.

a

Condition A: Enones were deprotonated at –78 ºC, followed by the addition of the Michael
acceptor. All experiments except for entry 8 were kept at –78 ºC for 2 h, then warmed up
to rt and stirred for 22 h. Entry 8 was quenched at –78 ºC after LDA deprotonation;
Condition B: Enones were deprotonated at –78 oC, followed by the addition of the Michael
acceptor, then warmed up to rt and refluxed for 3h. b2 eq. of Michael acceptor were used
in entries 1–13, each, and 1.2 eq. in entries 14–16. cN.R. = no reaction; ddeut. = deuteration
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of α-carbon confirmed by 1H NMR.
3.2.3

Nucleophilic Trapping of C-2 Cation

The use of a bicyclic[2.2.1]ketone substrate could be advantageous, because it
could permit the ready generation of varied aryl-containing analogs (e.g. 290) via arylmetal
1,2-addition reactions, followed by the conversion of the resulting alcohols to nitriles via
intermediate carbocations (Figure 2.2.2, 51). However, one disadvantage of the tertiary
alcohol to nitrile conversion is that it may only be high yielding for electron-rich arenes
able to facilitate the SN1-type transformation. Cyanation of a p-methoxylphenyl-stabilized
tertiary cation has been reported with monocyclic substrates,66 and there are also several
examples of trapping tertiary 2-norbornyl cations with nucleophiles.67, 84 This strategy was
examined by using model systems formed by treating camphor with 4-methoxyphenyl
magnesium bromide to generate alcohol 290, followed by acidic dehydration to generate
291. These were separately reacted with two different acids and TMSCN (Figure 3.2.3.1).
Upon treatment with BF3-OEt2 and TMSCN, 290 quickly dehydrated and rearranged to
give an inseparable mixture of dehydration product 291 and three other inseparable alkene
products with GC-MS and NMR analysis consistent with Wagner–Meerwein and Nametkin
rearrangements.85 The desired cyanation product 295 was not observed. Trapping of 2-
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norbornyl cation generated from 291 using TfOH66a was also not successful at a higher
temperature (-20 °C).

Figure 3.2.3.1 Attempted cyanation of camphor-derived alcohol 290 and alkene 291.
3.2.4

SNAr/SN2 using C-2 Anion

An endo-selective SNAr reaction with 2-cyano-5-norbornene and aryl fluoride
reported by Caron suggested a promising path to desirable α-arylated nitriles (Figure
3.2.4.1).65 In this approach, nitriles can be deprotonated with KHMDS and reacted with
both electron-rich and electron-poor aryl fluorides, with 297 reported as a single (endo),
presumably thermodynamic, diastereomer. Nitrile 298 was chosen to examine this
approach (Table 3.2.4.1). Under Caron’s optimal conditions, 298 did not undergo the SNAr
substitution with 1,2-difluorobenzene (entry 1). When forcing conditions were applied
(1,2-difluorobenzene as solvent, 115 ºC), only a trace amount of 299a was observed via
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LC-MS, and most of 298 was decomposed, as followed by TLC (entry 2). The substituted
bridgehead next to the reaction center has likely obstructed the approach of the arene
electrophile. However, alkylation reactions were successful using iodomethane and benzyl
bromide as electrophiles with quantitative conversion (entries 4, 5). CN-endo
diastereomers were the only products observed.

Figure 3.2.4.1 SNAr reported by Caron65 using 2-cyano-5-norbornene
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Entrya

Electrophile

Solvent

Conditions

Results

1

1,2-difluorobenzene (4 eq.)

THF

75 ºC, 12 h

N.R.b

2

1,2-difluorobenzene (excess)

neat

90–115 ºC, 24 h

trace
299ab

3

1,2-difluorobenzene (50 eq.) toluene

18-crown-6 (1 eq.), 100 ºC, 12
h

N.R.b

4

MeI (45 eq.)

toluene

55 ºC, 12 h

quant.
299bc

5

BnBr (5.5 eq.)

toluene

55 ºC, 12 h

quant.
299cc

a

To a solution of 298 (2 mg, 0.01 M) was added the indicated amount of
electrophile followed by KHMDS. bObserved by LC-MS. cEstimated NMR yield using
pentachloroethane as internal standard. N.R. = no reaction.
Table 3.2.4.1 Aryl/alkylation of secondary nitrile 298
3.3 Endgame Synthesis to 1st and 2nd Generation Bicyclic Sordarin
Analogs
This chapter describes the final stage synthesis toward two generations of bicyclic
sordarin analogs, starting from diene 258 described in chapter 3.1.2.3.

3.3.1

1st Generation Bicyclic Sordarin Analog

The first generation bicyclic sordarin (306, Figure 3.3.1.1) maintained the
minimum pharmacophore in a bicyclo[2.2.1]heptane skeleton and possessed a pentyl group
as the glycone substituent. This structure was designed mainly for the purpose of quick
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access and validation of a bicyclic sordarin analog. Therefore, the C-2 position was kept as
a secondary nitrile instead of a tertiary nitrile/aldehyde.
The synthesis commenced with a Diels-Alder reaction using silyloxy diene 258
and acrylonitrile which furnished the norbornene core 300 with approximately 1:1 d.r. The
TBS enol ether of 300 was selectively hydrolyzed to give ketone 301. The acetate of 301
was then hydrolyzed to give its corresponding primary alcohol. At this stage the two
diastereomers 302a and 302b were separated by chromatography, the stereochemistry was
assigned based on NMR analysis of 302b. As shown in Figure 3.3.1.1, in 302b, Hc and Hb
can be differentiated by observing their coupling constant with bridgehead proton Hd. No
coupling constant will be observed between Hb and Hd due to a dihedral angle approaching
90°.86 3Jab (9.2 Hz) is consistent with the cis coupling reported by Williamson for a nitrilesubstituted bicyclo[2.2.1]heptene (9.3 Hz).87 The primary alcohol of the CN-endo
diastereomer 302a was then protected with THP to give 303. An efficient Wittig reaction
converting 303 to 304 required generation of ylide under 90 °C. This was likely due to the
steric bulkiness from the neighboring TBDPS. To install the pentyl group as a glycone
substituent, TBDPS protected primary alcohol in 304 was cleaved by TBAF followed by
an alkylation to give 305. Finally, the THP protecting group was cleaved and oxidized to a
carboxylic acid to give the final bicyclic sordarin analog 306.
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Figure 3.3.1.1 Synthesis of the 1st generation bicyclic sordarin
3.3.2

2nd Generation Bicyclic Sordarin Analogs

The inactivity of the first-generation analog (See chapter 3.4) led to the hypothesis
that maybe a tertiary center at C-2 and/or a sophisticated glycone is needed for high
antifungal potency. Therefore, analogs with these two traits 312 and 313a-c were
synthesized (Figure 3.3.2.1).
The synthesis commenced with the intermediate 302 from the first-generation
synthesis. The primary alcohol of 302 was first oxidized to carboxylic acid and protected
as an PMB ester to give ester 307. 307 was then subjected to Wittig reaction to give olefin
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308. As was anticipated from the alkylation results discussed in chapter 3.2.4, direct
alkylation of 308 at the C-2 position gave the CN-endo product 309a-c exclusively. After
a TBAF deprotection of 309a-c, the stereochemistry was confirmed by observing nOe
between the C-2 alkyl groups and its neighboring protons as depicted in 310a-c. To conduct
the glycosidation, the primary alcohol was first converted into its corresponding triflate
311a-c, then reacted with deprotonated 314 or 315 to give final target compound 312 and
313a-c. The newly formed anomeric bond in 313a-c from this substitution was tentatively
assigned as equatorial based on NMR analysis on the chemical shift (4.5-4.6 ppm) and
coupling constants (4-6 Hz) of the anomeric proton from known analog.88 This result is
also consistent with a report from Schmidt,89 in which he demonstrated that sodium
alkoxide of glucopyranose prefers equatorial alkylation in room temperature. Since this is
a racemic synthesis, the final compounds each represent a racemic mixture of
diastereomers.
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Figure 3.3.2.1 Synthesis of the 2nd generation bicyclic sordarin analogs
3.4 Biological Results and Docking Studies

The antifungal activity of compounds 306, 312, 313a-c were assessed against C.
albicans, C. parapsilosis, P. variotii, and A. fumigatus. No antifungal activities were
observed at 8 µg/mL for compounds 306, 312, 313a and 313b. The assay for 313c only
went up to 4 µg/mL, and no antifungal activities were observed as well. (Figure 3.4.1)
Although it should be taken into consideration that these tested samples each contained
four isomers and only one is supposed to be active, it nonetheless suggested that their
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potencies are not in the same range as optimal analogs such as azasordarin 123 (Figure
2.2.3.1).

Figure 3.4.1 Antifungal assay result of 306, 312, 313a-c and reported low-potency
compound 316,12 317.90

The inactivity of these analogs led to their examination with docking studies. The
docking results are summarized in Table 3.4.1 below. The study is mainly aimed to
elucidate the extent of the carboxylic acid–aldehyde/nitrile pharmacophore’s deviation
from the parent sordarin molecule. Each picture shows a pose of sordarin (green) in eEF2
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binding site that is identified from the X-ray structure,15 and a superimposing sordarin
analog (various colors except green), whose poses were calculated by Molecular Forecaster
software.91
The sordarin molecule was docked first to benchmark the software. The resulting
pose is in great agreement with the reported crystal structure (last row, Table 3.4.1). The
high-potency azasordarin reported by BMS40 superposed its pharmacophore well with the
sordarin molecule (123, Table 3.4.1). This suggests that the docking calculation is
consistent with experimental data. The substitution of the aldehyde group in sordarin to a
nitrile did not appear to have a major impact in the poses of the molecules in eEF2 (318,
Table 3.4.1). This is also consistent with SAR studies reported by Merck.68 However,
bicyclic sordarin analogs 313b, 313c and 319 showed major deviations in the positioning
of the nitrile/carboxylic acid pharmacophore from the parent sordarin molecule. The
monocyclic analog 316 also gave similar poses with the second-generation analogs, with
the carboxylic acid deviating largely from its counterpart of the parent molecule. These
results could be attributed to two possibilities: The deletion of the C1-C2-C7 embedded
ring, or the deletion of the isopropyl group and the introduction of a terminal alkene. To
examine these hypotheses, analogs 320–324 were docked. The deletion of an isopropyl
group and the introduction of a terminal alkene on the bicyclo[2.2.1]heptane (320, 321) did
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not result in distortion of the molecule’s optimal pose and the docking scores are very close
to genuine sordarin. The deletion of the cyclopentane ring in sordarin also caused no major
pharmacophore deviation (322). In addition, the C1-C2-C7 embedded ring can be changed
from 6-membered to 5-membered without a major impact on the poses (323, 324). In
conclusion, the docking study suggests that a more rigid multicyclic ring system with a 5
or 6-membered ring enclosing C1-C2-C7 may be essential to keep the pharmacophore in
its optimal position when bound to eEF2.
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Score: -18.411

Score: -25.178

Score: -20.431

Score: -17.809
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Score: -19.918

Score: -28.954
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Score: -30.083

Score: -26.527

Score: -27.449

Score: -17.404
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Score: -30.097

Score: -20.836

Table 3.4.1 Docking results of sordarin analogs with eEF2. Sordarin x-ray structure is
shown in green, and lowest energy poses of docked analogs are shown in alternative
colors
3.5 Future Work

Based on the antifungal testing of 306, 312, and 313a-c, and the docking studies
described in Chapter 3.4, it is hypothesized that a rigid 5 or 6-membered ring embedding
C1-C2-C7 of the bicyclo[2.2.1]heptane core may be needed for the carboxylic acidaldehyde/nitrile pharmacophore to assume optimal orientations when binding eEF2.
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Therefore, two strategies to introduce such a rigid ring system are proposed.
A synthesis from (S)-camphor to introduce a 5-membered ring is proposed in
Figure 3.5.1. This strategy could provide an enantiopure sordarin analog from a cheap
starting material. Trans-π-bromocamphor 325 can be prepared from a known protocol
using (S)-camphor.92 A substitution using BnOH will give benzyl ether 326. Despite the
fact that the primary bromide is next to a quaternary center, a SN2 reaction is feasible at
this position as was demonstrated in Corey’s report.92b Chelate-directed C-H activation
using oxime reported by Sanford93 could be used to oxidize the bridgehead methyl group
to give acetate 327, and the oxime can then be hydrolyzed to give ketone 328. The acetate
of 328 is then cleaved and oxidized to carboxylic acid, followed by formation of the t-butyl
ester 329. Cyanohydrin 330 can then be derived from ketone 329 by using TMSCN as a
cyanide source, with related reactions furnishing the desired CN-endo diastereomer in at
least a 2:1 ratio.94 Alcohol 330 will then be subjected to Suárez oxidative cyclization to
give ether 331.95 The benzyl protected primary alcohol will then be released to give 332.
Following the same glycosidation procedure described in chapter 3.3.2, a final testable
nitrile 333 can be obtained, and it can be optionally reduced to the aldehyde analog 334.
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Figure 3.5.1 Proposed synthetic scheme for analogs with C1-C2-C7 embedded 5membered ring

Another strategy which could introduce a C1-C2-C7 embedded 6-membered ring
can be taken by using secondary nitrile 308 (Figure 3.5.2). 308 was a key intermediate
described in the 2nd-generation analog synthesis. A direct alkylation of 308 with PMBBr is
expected to happen exclusively on the exo-face, giving tertiary nitrile 336. The TBDPS
protected alcohol will then be released and oxidized to aldehyde 337. Tollens conditions
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will convert 337 to diol 338.96 The primary alcohol cis to the PMB group will be able to
add to the oxidized benzylic position upon treatment with DDQ. Trauner has reported a
similar example.96a This conversion will furnish a C1-C2-C7 embedded 6-membered ring
giving ether 339. Following the same glycosidation procedure described in chapter 3.3.2.
glycone 314 can be installed to give the final sordarin analog 340.

Figure 3.5.2 Proposed synthetic scheme for analogs with C1-C2-C7 embedded 6membered ring
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4.0 Experimental Procedures and Characterization Data

General Information. Unless otherwise noted, all reagents and solvents, including
anhydrous solvents, were purchased from commercial vendors and used as received.
Reactions were performed in ventilated fume hoods with magnetic stirring and heated in
oil baths, unless otherwise noted. Reactions were performed in air, unless otherwise noted.
Chilled reactions (below –10 °C) were performed in an acetone bath in a vacuum dewar,
using a Neslab CC 100 immersion cooler. Unless otherwise specified, reactions were not
run under N2 atmosphere. Deionized water was purified by charcoal filtration and used for
reaction workups and in reactions with water. NMR spectra were recorded on Varian 300
MHz or 400 MHz spectrometers as indicated. Proton and carbon chemical shifts are
reported in parts per million (ppm; δ) relative to tetramethylsilane (1H δ 0), or CDCl3 (13C
δ 77.16), (CD3)2CO (1H δ 2.05, 13C δ 29.84), d6-DMSO (1H δ 2.50, 13C δ 39.5), or CD3OD
(1H δ 3.31, 13C δ 49.00). NMR data are reported as follows: chemical shifts, multiplicity
(obs = obscured, app = apparent, br = broad, s = singlet, d = doublet, t = triplet, q = quartet,
m = multiplet, comp = complex overlapping signals); coupling constant(s) in Hz;
integration. Unless otherwise indicated, NMR data were collected at 25 °C. Filtration was
performed by vacuum using VWR Grade 413 filter paper, unless otherwise noted.
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Analytical thin layer chromatography (TLC) was performed on Agela Technologies glass
plates with 0.20 mm silica gel with F254 indicator. Visualization was accomplished with
UV light (254 nm) and KMnO4 stain, unless otherwise noted. Flash chromatography was
performed using Biotage SNAP cartridges filled with 40-60 µm silica gel on Biotage
Isolera automated chromatography systems with photodiode array UV detectors. Unless
otherwise mentioned, columns were loaded with crude compounds as DCM solutions.
Tandem liquid chromatography/mass spectrometry (LC-MS) was performed on a
Shimadzu LCMS-2020 with autosampler, photodiode array detector, and singlequadrupole MS with ESI and APCI dual ionization, using a Peak Scientific nitrogen
generator. Unless otherwise noted, a standard LC-MS method was used to analyze
reactions and reaction products: Phenomenex Gemini C18 column (100 x 4.6 mm, 3 µm
particle size, 110 A pore size); column temperature 40 °C; 5 µL of sample in MeOH or
CH3CN at a nominal concentration of 1 mg/mL was injected, and peaks were eluted with
a gradient of 25−95% CH3CN/H2O (both with 0.1% formic acid) over 5 min., then 95%
CH3CN/H2O for 2 min. Purity was measured by UV absorbance at 210 or 254 nm.
Preparative liquid chromatography was performed on a Shimadzu LC-20AP preparative
HPLC with autosampler, dual wavelength detector, and fraction collector. Samples purified
by preparative HPLC were loaded as DMSO solutions. Chemical names were generated
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and select chemical properties were calculated using either ChemAxon Marvin suite or
ChemDraw Professional 15.1. NMR data were processed using either MestreNova or
ACD/NMR Processor Academic Edition software. High-resolution mass spectra (HRMS)
were obtained at the University of Cincinnati Environmental Analysis Service Center
(EASC) with an Agilent 6540 Accurate-Mass with Q-TOF. Catalyst 281 was prepared
according to a published protocol.97

4.1 Cyclopentanone Synthesis

4.1.1

Trost AAA Route

Methyl (4S)-4-methyl-2-oxo-4-vinyltetrahydrofuran-3-carboxylate. To a 100 mL
round bottom flask was added Pd2(dba)3 (140 mg, 0.153 mmol), (S,S)-Trost Ligand (316.8
mg, 0.459 mmol), and a stirbar. The flask was then placed under reduced pressure (vacuum
pump) for 10 seconds and refilled with argon. This purging process was repeated for 5
times, after being placed under an argon atmosphere, dry DCM (30 mL) was added and the
resulting dark purple solution was stirred at room temperature until it turned into a deep
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orange color (5 min). During this time, neat dimethyl malonate (1.93 mL, 16.82 mmol) was
added. Finally, 2-methyl-2-vinyloxirane (1.5 mL, 15.29 mmol) was added to the reaction
mixture. Stirring was continued for 30 min at rt, at which point, the color of the solution
turned into orange again. The solvent was removed in vacuo to give a crude yellow oil, the
crude sample was then purified by chromatography (0-40% EtOAc/Hexane) to give 204 as
a clear colorless oil, 973 mg, 35% yield. ESI+APCI LC-MS: m/z 185 (M+H+). 1H NMR
(300 MHz, Chloroform-d) δ 6.02 – 5.76 (m, 1H), 5.32 – 5.08 (m, 2H), 4.53 – 3.98 (m, 1H),
4.24 – 4.13 (m, 1H), 3.79 (s, 1H), 3.74 (s, 1H), 3.48 (s, 1H), 3.29 (s, 1H), 1.40 (s, 1H), 1.26
(s, 1H);

13

C NMR (75 MHz, CDCl3) δ 171.9, 171.8, 167.1, 166.9, 140.3, 136.9, 117.0,

115.5, 76.6, 76.6, 58.5, 56.1, 52.9, 52.9, 46.4, 46.2, 24.4, 19.4.

Methyl (4S)-3-allyl-4-methyl-2-oxo-4-vinyltetrahydrofuran-3-carboxylate. 204 (14
mg, 0.076 mmol) was dissolved in 1 mL THF in a 20 mL vial. Allyl bromide (13 uL, 0.152
mmol) was added, followed by the addition of DBU (23 uL, 0.152 mmol). The mixture
was stirred for 5 h, then the mixture was diluted with 3 mL EtOAc and washed with water
(2 mL). The organic phase was separated and the aqueous phase was extracted with 3 x 1
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mL EtOAc. The combined organic phase was dried over Na2SO4 and concentrated to give
crude 205 as a colorless oil. The crude NMR indicated crude 205 contains mostly the
desired product with very little impurity, the sample was recovered and used in the next
step without any further purification. 1H NMR (400 MHz, Chloroform-d) δ 6.16 – 5.68 (m,
2H), 5.39 – 4.90 (m, 4H), 4.32 (dd, J = 34.1, 8.8 Hz, 1H), 4.03 (dd, J = 39.9, 8.9 Hz, 1H),
3.83 – 3.64 (m, 3H), 2.69 – 2.34 (m, 2H), 1.44 – 1.11 (m, 3H).

Methyl

(3aR,6aS)-6a-methyl-3-oxo-4,6a-dihydro-1H-cyclopenta[c]furan-3a(3H)-

carboxylate. Crude 205 (6.7 mg) was dissolved in 2 mL DCM in a 20 mL vial. Grubbs' GII catalyst (3.2 mg, 0.004 mmol) was added, the vial was then purged 3 times with N2, the
mixture was then stirred overnight. The mixture was concentrated to give a black oil, this
crude sample was then dissolved in 5 mL 30% EtOAc in hexane and passed through a silica
gel packed pipette and eluted with additional 5 mL 30% EtOAc in hexane solution. The
resulted solution was then concentrated to give a gray oil. The sample was purified by
chromatography (5%-8%-20% EtOAc/Hexane) to give unreacted 205 as a colorless oil, 3.2
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mg 19% yield, and 206 as a colorless oil, 6.7 mg 45% yield over 2 steps. 1H NMR (300
MHz, Chloroform-d) δ 5.79 (ddd, J = 5.7, 2.6, 1.9 Hz, 1H), 5.46 (ddd, J = 5.7, 2.7, 1.6 Hz,
1H), 4.31 (d, J = 8.9 Hz, 1H), 4.22 – 4.16 (m, 1H), 3.81 – 3.77 (m, 3H), 3.30 – 3.20 (m,
1H), 2.99 – 2.89 (m, 1H), 1.13 (s, 3H).

(3aS)-3a-methyl-3,3a,6,6a-tetrahydro-1H-cyclopenta[c]furan-1-one. 206 (6.7 mg,
0.034 mmol) was dissolved in 2 mL DMSO in a 20 mL vial. LiCl (2.9 mg, 0.068 mmol)
was added, the mixture was then heated to 140 oC and stirred for 48h. To the mixture was
added 5 mL EtOAc and 10 mL water, the organic phase was separated and washed with
another 5 mL of water and 5 mL of brine. The resulting organic phase was dried over
Na2SO4 and concentrated to give crude 207 as a yellow oil. The crude NMR indicated the
desired product was formed without any other byproducts. The crude sample was recovered
and used in next step directly. 1H NMR (400 MHz, Chloroform-d) δ 5.80 – 5.73 (m, 1H),
5.57 (dd, J = 5.5, 1.9 Hz, 1H), 4.28 (d, J = 9.2 Hz, 1H), 4.18 – 4.06 (m, 1H), 2.83 – 2.63
(m, 3H), 1.44 – 1.04 (m, 3H).
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(4S)-3-allyl-4-methyl-4-vinyldihydrofuran-2(3H)-one. Crude 205 (923 mg, 4.116
mmol) was dissolved in 30 mL DMSO in a 100 mL flask. LiCl (348.9 mg, 8.232 mmol)
was added, the flask was then purged with N2 capped with plastic cap loosely and heated
to 140 oC and stirred for 24 h. The mixture was then added 30 mL EtOAc and 30 mL water,
the organic phase was separated and washed with another 20 mL of water and 20 mL of
brine. The resulting organic phase was dried over Na2SO4 and concentrated to give crude
208 as a brown oil, 261 mg, 38% yield over 2 steps. 1H NMR (400 MHz, Chloroform-d) δ
5.97 – 5.72 (m, 2H), 5.32 – 4.93 (m, 4H), 4.21 – 3.82 (m, 2H), 2.58 – 2.04 (m, 3H), 1.40 –
1.02 (m, 3H).

Benzyl (3S)-2-allyl-3-((benzyloxy)methyl)-3-methylpent-4-enoate. Crushed KOH
(193.2 mg, 3.444 mmol) was added to a toluene (6 mL) solution of 208 (108 mg, 0.650
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mmol) and benzyl bromide (0.49 mL, 4.127 mmol). The reaction mixture was stirred at
110 oC for 24 h. TLC indicated complete consumption of the starting material, the reaction
mixture was diluted with 3 mL EtOAc and added sat. aq. NH4Cl solution (3 mL). The
organic phase was separated and the aqueous phase was extracted with EtOAc (3 x 3 mL).
The combined organic phase was dried over Na2SO4 and concentrated to give a crude oil
sample which is purified by chromatography (0-8% EtOAc/Hexane) to give 209 as a
colorless oil, 199 mg, 84% yield. ESI+APCI LC-MS: m/z 365 (M+H+). 1H NMR (400
MHz, Chloroform-d) δ 7.36 – 7.24 (m, 10H), 6.09 (dd, J = 17.6, 10.9 Hz, 1H), 5.87 (dd, J
= 17.6, 10.9 Hz, 1H), 5.74 – 5.60 (m, 1H), 5.17 – 4.88 (m, 6H), 4.51 – 4.29 (m, 2H), 3.36
– 3.14 (m, 2H), 2.75 (ddd, J = 13.4, 11.9, 3.2 Hz, 1H), 2.41 – 2.25 (m, 1H), 2.25 – 2.11 (m,
1H), 1.12 (d, J = 10.3 Hz, 3H); 13C NMR (75 MHz, CDCl3) δ 174.1, 174.1, 142.4, 141.9,
138.6, 138.6, 136.3, 136.3, 136.2, 136.1, 128.7, 128.7, 128.6, 128.6, 128.5, 128.5, 128.3,
127.7, 127.6, 116.8, 116.7, 114.6, 114.1, 76.6, 73.4, 73.4, 66.2, 66.1, 51.3, 50.8, 43.7, 43.4,
32.4, 32.2, 18.6, 17.8.
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Benzyl

(2S)-2-((benzyloxy)methyl)-2-methylcyclopent-3-ene-1-carboxylate

and

methyl

(2S)-2-((benzyloxy)methyl)-2-methylcyclopent-3-ene-1-carboxylate.

209

(293.1 mg, 0.804 mmol) was dissolved in 10 mL DCM in a 20 mL vial. Grubbs' G-II
catalyst (34.1 mg, 0.04 mmol) was added, the vial was then purged 3 times with N2, the
mixture was then stirred 16h. LCMS indicated complete consumption of the starting
material, the mixture was concentrated to give a black oil. This crude sample was then
dissolved in 10 mL MeOH and stirred at 60 oC for 24h, then the mixture was concentrated
to give a dark oil and purified by chromatography (0-5% EtOAc/Hexane) to give an
inseparable 4:1 mixture of 210 and 212 as a yellow oil, 138 mg, 54% yield. 1H NMR (400
MHz, Chloroform-d) δ 7.38 – 7.19 (m, 8H), 5.75 – 5.65 (m, 1H), 5.53 – 5.39 (m, 1H), 5.18
– 4.82 (m, 2H), 4.64 – 4.27 (m, 2H), 3.74 – 3.37 (m, 2H), 3.33 – 3.15 (m, 1H), 3.00 – 2.72
(m, 1H), 2.62 – 2.41 (m, 1H), 1.35 (d, J = 23.2 Hz, 1H), 0.87 (d, J = 18.9 Hz, 2H); 13C
NMR (101 MHz, cdcl3) δ 174.4, 173.8, 173.7, 138.6, 138.6, 138.6, 136.7, 136.7, 136.3,
136.2, 136.1, 129.2, 128.5, 128.5, 128.4, 128.3, 128.3, 128.3, 128.2, 128.1, 128.1, 128.0,
127.5, 127.3, 127.3, 127.3, 76.2, 74.1, 73.3, 73.2, 73.1, 66.2, 66.1, 53.0, 52.9, 52.8, 51.9,
51.4, 47.8, 47.8, 35.2, 35.1, 33.9, 33.9, 30.0, 24.3, 18.8, 18.8.

4.1.2

Pd. Catalyzed Carbonylation Route
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4.1.2.1 Lipase-catalyzed Transesterification Route

2-(hydroxymethyl)-2-methylcyclopentan-1-one. To a 250 mL round bottom flask was
charged with ethyl 2-oxocyclopentanecarboxylate (10 mL, 69.1 mmol) dissolved in 150
mL acetone. K2CO3 (28.6 g, 207 mmol) and MeI (8.2 mL, 131 mmol) was added
subsequently. The mixture was then heated to reflux for 1 h. LCMS indicated completion
of the reaction, the mixture was passed through a Celite pad. The filtrate was concentrated
and re-dissolved in EtOAc (100 mL) washed with 50 mL NH4Cl solution and brine (50
mL). The resulting solution was dried over Na2SO4 and concentrated to give a colorless
crude oil which is used in next step without any further purification.
To a 250 mL round bottom flask was charged with the crude sample from the previous step
(10.4 g, 61.1 mmol) dissolved in 100 mL toluene, ethylene glycol (10.2 mL, 183 mmol)
and p-TsOH monohydrate (1.16 g,6.11 mmol) was added subsequently. The flask was fitted
with a Dean-Stark trap and heated to 120 oC for 24h, to the mixture was then added K2CO3
(5g) and filtered through a Celite pad rinsed with 50 mL toluene, the resulting mixture was

111

then concentrated to give a crude colorless oil, 13.1 g, 36%. The crude sample was used
directly in the next step.
To a 500 mL round bottom flask was charged with LiAlH4 (2.78 g, 73.3 mmol) dissolved
in Et2O (100 mL). The mixture was cooled down to 0 oC, crude sample from the previous
step (4.79 g, 22.4 mmol) in 15 mL Et2O was added to the mixture over 5 min. The mixture
was then stirred at 0 oC for 1 h. TLC indicated completion of the reaction, the mixture was
quenched by adding EtOAc dropwise until no more gas was released. To this suspension
was added sat aq. potassium sodium tartrate (300 mL) and stirred for 6 h. Then the organic
phase was separated and the aqueous phase was extracted with 3 x 100 mL EtOAc. The
combined organic phase was washed with brine (100 mL) and dried over Na2SO4,
concentrated to give a colorless crude oil. This crude oil was then dissolved in Et2O (100
mL). 2N HCl (11.2 mL) was added. The mixture was stirred at rt for 2h, then NaHCO3 (50
mL) was added. The organic phase was separated and the aqueous phase was extracted
with 3 x 50 mL Et2O, the combined organic phase was washed with brine (100 mL) and
dried over Na2SO4, concentrated to give a crude oil which is then purified by
chromatography (0%-40% EtOAc/Hexane) to give 238 as a colorless oil, 783 mg, 3% over
4 steps. 1H NMR (300 MHz, Chloroform-d) δ 4.16 (qd, J = 7.1, 1.3 Hz, 2H), 2.63 – 2.22
(m, 3H), 2.14 – 1.76 (m, 3H), 1.38 – 1.14 (m, 6H). Product previously characterized in the
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literature98.

(R)-(1-methyl-2-oxocyclopentyl)methyl acetate. 238 (47.9 mg, 0.374 mmol) was
dissolved in 20 mL benzene, to this mixture was added vinyl acetate (0.1 mL, 1.121 mmol)
and Amano PS lipase (29.2 mg). The mixture was then heated to 50 oC and stirred for 24
h. After 24h at 50 oC, 1 mL of the mixture was taken and filtered through a syringe filter
concentrated and a crude NMR was taken. NMR indicated the ratio of desired product :
SM= 1:2. the mixture was then filtered through syringe filter, concentrated and re-dissolved
in benzene (5 mL). Vinyl acetate (0.1 mL, 1.121 mmol) and Amano PS lipase (29.2 mg)
was added. The mixture was then heated to 50 oC and stirred for another 24 h. 1 mL of the
mixture was taken and filtered through a syringe filter concentrated and a crude NMR was
taken. NMR indicated ratio of desired product 239 : SM= 1:1, suggesting a 50% conversion.
1

H NMR (300 MHz, Chloroform-d) δ 4.04 (d, J = 1.8 Hz, 2H), 2.46 – 2.14 (m, 2H), 2.04

(s, 3H), 2.02 – 1.69 (m, 4H), 1.04 (s, 3H). Product previously characterized in the
literature47.

4.1.2.2 Baker’s yeast Reduction Route

113

Ethyl (1R,2S)-2-hydroxycyclopentane-1-carboxylate. To a 2L Erlenmeyer flask was
charged with sucrose (180 g, 0.53 mol), dissolved in 900 mL warm water (30 oC). Baker's
yeast (90 g) was added, upon which, large amount of bubble and foam was observed. The
mixture was stirred at 30 oC for 30 min, ethyl 2-oxocyclopentanecarboxylate (10 mL, 69.09
mmol) was added, then the mixture was stirred for 48h at 25 oC. The mixture was filtered
through a Bucher funnel with filter paper to give a slightly yellow filtrate. To the filter cake
was added 200 mL MeOH to elute the emulsion. The combined filtrate was then extracted
with 200 mL EtOAc, then the aqueous phase was saturated with NaCl and extracted with
3 x 200 mL EtOAc. The combined organic phase was dried over Na2SO4 and concentrated
to give a brown oil crude product (8.2 g), which is then purified by chromatography (020% EtOAc/Hexane) to give 244 as a yellow oil, 5.7 g, 50% yield. 1H NMR (400 MHz,
Chloroform-d) δ 4.44 (q, J = 3.9 Hz, 1H), 4.19 (q, J = 7.1 Hz, 2H), 3.17 (s, 1H), 2.68 (ddd,
J = 10.1, 8.7, 4.3 Hz, 1H), 2.08 – 1.87 (m, 3H), 1.83 – 1.73 (m, 2H), 1.70 – 1.57 (m, 1H),
1.29 (t, J = 7.1 Hz, 3H); Product previously characterized in the literature99.
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(S)-2-(((tert-butyldiphenylsilyl)oxy)methyl)cyclopentan-1-one. To a 500 mL round
bottom flask was charged LiAlH4 (65.3 mg, 1.721 mmol) and Et2O (200 mL). This mixture
was cooled to 0 oC, 244 (4.767 g, 30.13 mmol) in Et2O (50 mL) was added and the mixture
was stirred at the same temperature for 1h, at which point, TLC indicated complete
consumption of the starting material. The reaction was quenched by adding EtOAc
dropwise until no gas was forming, then saturated potassium sodium tartrate solution (50
mL) was added. The mixture was stirred for 4h, the mixture was transferred to a separatory
funnel. The organic phase was separated and the aqueous phase was extracted with Et2O
(3 x 50 mL). The combined organic phase was washed with brine (30 mL) dried over
Na2SO4, concentrated to give a colorless oily crude product which is used directly in next
step without any further purification.
The crude product from last step was dissolve in 10 mL DCM in a 50 mL round bottom
flask. To the mixture was added imidazole (47.2 mg, 0.694 mmol) and TBDPSCl (90 ul,
0.347 mmol). The mixture was stirred at rt for 24h, TLC indicated incomplete consumption
of the starting material, then to the mixture was added another portion of imidazole (20.4

115

mg, 0.3 mmol) and TBDPSCl (104 ul, 0.4 mmol) and stirred for another 24 h. TLC
indicated complete consumption of the starting material. NH4Cl solution (10 mL) was
added, the organic phase was separated and the aqueous phase was extracted with DCM 3
x 10 mL, the combined organic phase was washed with brine 10 mL, dried over Na2SO4
concentrated to give a colorless oily crude product which is purified through
chromatography (0-15% EtOAc/Hexane) to give a colorless oil which was then dissolved
in 20 mL DCM in a 100 mL round bottom flask. Dess-Martin periodinane (488 mg, 1.15
mmol) was added. The mixture was stirred at rt for 16h, LCMS indicated complete
consumption of the starting material. 1:1 solution of Na2S2O3 and NaHCO3 (20 mL) was
added, the organic phase was separated and the aqueous phase was extracted with DCM 3
x 20 mL. The combined organic phase was washed with brine (20 mL), dried over Na2SO4,
concentrated to give a semi-solid crude product, which is then purified by chromatography
DCM/Hexane 0-65% to give 245 as a white solid, 140 mg, 40 % yield over 3 steps. 1H
NMR (300 MHz, Chloroform-d) δ 7.68 – 7.59 (m, 4H), 7.47 – 7.32 (m, 6H), 3.95 (dd, J =
10.0, 4.5 Hz, 1H), 3.76 (dd, J = 10.0, 3.1 Hz, 1H), 2.39 – 1.96 (m, 6H), 1.89 – 1.71 (m,
1H), 1.02 (s, 9H). Product previously characterized in the literature.100
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(S)-5-(((tert-butyldiphenylsilyl)oxy)methyl)cyclopent-1-en-1-yl
trifluoromethanesulfonate. Diisopropylamine (17 uL, 0.119 mmol) was dissolved in 1
mL THF at 0 oC. n-BuLi 1.2 M solution in hexane (89 uL, 0.11 mmol) was added, the
mixture was stirred for 5 min, cooled to -78 oC. 245 (25.9 mg, 0.073 mol) in THF (0.5 mL)
was added. The mixture was then stirred for 1 h, a solution of PhNTf2 (39.4 mg, 0.11 mmol)
in THF (0.5 mL) was added. The mixture was stirred at -78 oC for 2h. NaHCO3 solution (1
mL) and EtOAc (1 mL) was added, the organic phase was separated and the aqueous phase
was extracted with 3 x 1 mL EtOAc. The combined organic phase was dried over Na2SO4
concentrated to give a crude yellow oily sample which is then purified by chromatography
(0-3% EtOAc/Hexane) to give 248 as a white solid, 7.4 mg, 21% yield. 1H NMR (400 MHz,
Chloroform-d) δ 7.65 (ddt, J = 7.3, 3.4, 1.6 Hz, 4H), 7.55 – 7.48 (m, 6H), 5.75 (q, J = 2.4
Hz, 1H), 3.74 (dd, J = 10.3, 4.6 Hz, 1H), 3.67 (dd, J = 10.3, 3.7 Hz, 1H), 3.03 – 2.90 (m,
1H), 2.52 – 2.31 (m, 2H), 2.16 (dtd, J = 13.1, 9.2, 5.7 Hz, 1H), 2.08 – 1.97 (m, 1H), 1.04
(s, 9H).
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Methyl

(R)-5-(((tert-butyldiphenylsilyl)oxy)methyl)cyclopent-1-ene-1-carboxylate.

To a solution of 248 (23 mg, 0.047 mmol) in MeOH/DMF (4:1, 1 mL) were added Et3N
(13 ul, 0.095 mmol) and Pd(PPh3)4 (5.5 mg, 5 umol) in a 20 mL vial at room temperature.
The solution was blown through by CO for 10 min, then the flask was sealed and put under
vacuum and refilled with CO using a balloon. This process was repeated for 3 times, then
the reaction mixture was stirred for 2.5 h at 40 °C. The reaction mixture was quenched with
aq. NH4Cl (1 mL). The organic layer was separated and the aqueous layer was extracted
with Et2O (3 x 2 mL). The combined organic layer was washed with brine and dried over
anhydrous MgSO4. The solvent was evaporated under reduced pressure to give a crude
product as a green oil, this crude product was dissolved in 5% EtOAc/Hexane and passed
through a silica gel packed pipette concentrated to give 249 as a colorless oil, 5.3 mg, 28%
yield. 1H NMR (400 MHz, Chloroform-d) δ 7.69 – 7.58 (m, 4H), 7.43 – 7.34 (m, 6H), 6.89
(td, J = 2.6, 1.4 Hz, 1H), 3.81 (dd, J = 9.8, 3.6 Hz, 1H), 3.70 (dd, J = 9.8, 6.0 Hz, 1H), 3.64
(s, 3H), 3.21 – 3.03 (m, 1H), 2.62 – 2.50 (m, 1H), 2.47 – 2.34 (m, 1H), 2.16 – 2.04 (m, 2H),
1.02 (s, 9H).
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Methyl

(R)-5-(((tert-butyldiphenylsilyl)oxy)methyl)-3-oxocyclopent-1-ene-1-

carboxylate. 249 (382.7 mg, 0.97 mmol) was dissolved in DCM (5 mL) in a 20 mL vial,
Pd(OH)2/C (20%) (34 mg, 48 umol), K2CO3 (33.5 mg, 0.24 mmol) was added. The
mixture was cooled to 4 °C and t-butylhydroperoxide (TBHP) (0.66 mL, 4.849 mmol) was
added with vigorous stirring. The vial was sealed and allowed to warm up to rt. The reaction
mixture was stirred at 24 °C for 48h, TLC showed incomplete consumption of starting
material, t-BuOOH (0.1 mL) then Pd(OH)2/C (20%) (10 mg), K2CO3 (30 mg) was added,
after another 48h, TLC showed small amount of starting material remaining, thus another
portion of t-BuOOH (0.2 mL) was added, the mixture was stirred for another 2h, the
solution was then diluted with DCM and passed through a pipette packed with silica gel
and Na2SO4, washed with DCM, concentrated to give a colorless oil-like crude sample,
which was purified by chromatography, 0-20% EtOAc/Hexane to give 250 as a colorless
oil, became white solid after sitting in atmosphere, 196.4 mg, 50% yield. 1H NMR (400
MHz, Chloroform-d) δ 7.69 – 7.51 (m, 4H), 7.44 – 7.33 (m, 6H), 6.82 (d, J = 1.6 Hz, 1H),
3.96 (dd, J = 10.0, 3.8 Hz, 1H), 3.89 – 3.80 (m, 1H), 3.76 (s, 3H), 3.41 – 3.30 (m, 1H), 2.64
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– 2.58 (m, 2H), 0.99 (s, 9H);

13

C NMR (101 MHz, cdcl3) δ 208.2, 164.4, 163.2, 139.7,

135.5, 133.0, 132.9, 129.8, 129.8, 127.8, 127.7, 127.7, 63.4, 52.3, 42.5, 40.0, 26.7, 26.7,
19.2. IR (thin film) 2931, 2857, 1719, 1215, 1104, 821, 699 cm-1.

4.1.2.3 Racemic Route

2-(((tert-butyldiphenylsilyl)oxy)methyl)cyclopentan-1-one.

2-

(Hydroxymethyl)cyclopentan-1-one prepared via a literature protocol101 (25.81 g, 226.1
mmol) was added to a 1 L round bottom flask with stir bar in DCM (350 mL), sealed with
a septum under nitrogen, and cooled in an ice bath. Imidazole (16.93 g, 248.7 mmol) was
added, followed by TBDPSCl (64.7 mL, 248.7 mmol). The reaction was removed from the
ice bath and stirred for 4 h, after which time TLC (30% EtOAc/hexanes) showed complete
consumption of the starting material. Sat. aq. NH4Cl (150 mL) was added, the organic
phase was separated, and the aqueous phase was re-extracted with DCM (3 x 150 mL). The
combined organics were washed with brine (100 mL), dried over Na2SO4, filtered, and
concentrated to give a pale green solid. The crude material was recrystallized by adding
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MeOH (150 mL), then heating with a heat gun until all solid dissolved. The solution was
cooled for 10 min., then cooled in an ice bath for 3 h. The resulting crystals were filtered
with a Buchner funnel and washed with ice-cold MeOH, then dried under vacuum, yielding
silylether 252 (49.03 g, 62%) as a colorless solid, consistent with literature data.102 Rf = 0.5
(5% EtOAc/hexanes). 1H NMR (300 MHz, CDCl3) δ 7.69 – 7.60 (m, 4H), 7.48 – 7.30 (m,
6H), 3.95 (dd, J = 10.0, 4.6 Hz, 1H), 3.76 (dd, J = 10.0, 3.1 Hz, 1H), 2.40 – 1.97 (m, 6H),
1.90 – 1.67 (m, 1H), 1.02 (s, 9H).

5-(((tert-butyldiphenylsilyl)oxy)methyl)cyclopent-1-en-1-yl
trifluoromethanesulfonate. Silylether 252 (3.00 g, 8.51 mmol) and PhNTf2 (5.77 g, 16.1
mmol) were added to a 250 mL round bottom flask with stir bar and sealed under nitrogen.
Anhydrous THF (100 mL) was added by syringe, and the resulting solution was cooled to
–40 oC. NaHMDS (2 M solution in THF, 16.6 mL, 33.2 mmol) was added dropwise and
the reaction was stirred at the same temperature for 45 min, at which point TLC (5%
EtOAc/hexanes) showed complete consumption of the starting material. The reaction was
quenched with sat. aq. NH4Cl solution (100 mL) and extracted with EtOAc (3 x 50 mL),
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then the combined organics were washed with brine, dried over Na2SO4, and concentrated
to give a brown oil. The crude oil was then dissolved in hexanes and added by pipet to a
25 g silica gel pad in a sintered glass funnel, then eluted with hexanes (500 mL) and
concentrated to give triflate 253 (4.13 g, 100%) as a yellow oil. Rf = 0.67 (3%
EtOAc/hexanes). 1H NMR (300 MHz, CDCl3) δ 7.70 – 7.61 (m, 4H), 7.45 – 7.33 (m, 6H),
5.74 (app q, J = 2.4 Hz, 1H), 3.75 (dd, J = 10.3, 4.6 Hz, 1H), 3.67 (dd, J = 10.3, 3.7 Hz,
1H), 3.03 – 2.89 (m, 1H), 2.53 – 2.28 (m, 2H), 2.23 – 2.09 (m, 1H), 2.09 – 1.92 (m, 1H),
1.05 (s, 9H) ppm. 13C NMR (75 MHz, CDCl3) δ 149.6, 135.8, 135.8, 133.6, 133.4, 130.0,
130.0, 128.0, 119.3, 63.6, 46.1, 27.2, 27.0, 24.8, 19.5. IR (thin film): ν = 2932, 2859, 1421,
1206, 1139, 1110, 998, 822, 699 cm-1. HRMS (ESI+): calcd for C23H28F3O4SSi [M+H]
485.1430; found 485.1427.

Methyl

5-(((tert-butyldiphenylsilyl)oxy)methyl)cyclopent-1-ene-1-carboxylate.

Triflate 253 (24.4 g, 50.4 mmol) and Pd(dppf)Cl2 · CH2Cl2 (1.23 g, 1.51 mmol) were
charged to a 1 L round bottom flask with stir bar and sealed with a septum under nitrogen.
MeOH/DMSO (1:1, 500 mL) was added by syringe, followed by NEt3 (21.1 mL, 151
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mmol). A balloon with needle adapter and 8" steel needle containing carbon monoxide
(CO) (toxic; dispensed in a fume hood and transported in a sealed box) was attached to the
flask, and the reaction solution was bubbled with CO for 5 min. by temporarily attaching a
vent to an oil bubbler. The vent needle was removed and a new balloon of CO was attached,
then the reaction was heated at 75 oC for 4 days. TLC (3% EtOAc/hexanes) indicated
complete consumption of the starting material. One-third of the reaction mixture (~170
mL) was added to a 2 L separatory funnel charged with half-saturated NH4Cl solution (450
mL) and EtOAc (600 mL), the organic phase was separated, and the aqueous phase was
extracted with EtOAc (2 x 150 mL), and the combined organics were washed with brine.
This process was repeated for the other two portions of the reaction solution. The combined
organics were dried over Na2SO4, filtered, and concentrated to give a dark tar, which was
purified by column chromatography on a 300 g column (EtOAc/hexanes, 0–3%) to give
ester 254 (16.2 g, 82%) as a colorless oil. Rf = 0.5 (3% EtOAc/hexanes). 1H NMR (400
MHz, CDCl3) δ 7.73 – 7.60 (m, 4H), 7.47 – 7.33 (m, 6H), 6.90 (td, J = 2.6, 1.2 Hz, 1H),
3.84 (dd, J = 9.8, 3.6 Hz, 1H), 3.73 (ddd, J = 9.8, 6.0, 0.6 Hz, 1H), 3.66 (s, 3H), 3.22 – 3.08
(m, 1H), 2.64 – 2.51 (m, 1H), 2.49 – 2.36 (m, 1H), 2.18 – 2.08 (m, 2H), 1.05 (s, 9H). 13C
NMR (101 MHz, CDCl3) δ 165.4, 146.3, 136.3, 135.6, 135.6, 133.9, 133.8, 129.5, 129.5,
127.6, 127.6, 65.3, 51.2, 46.9, 32.2, 27.4, 26.8, 19.3. IR (thin film): ν = 2931, 2857, 1714,
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1427, 1102, 1028, 738, 698 cm-1. HRMS (ESI+): calcd for C24H31O3Si [M+H] 395.2042;
found 395.2039.

Methyl 5-(((tert-butyldiphenylsilyl)oxy)methyl)-3-oxocyclopent-1-ene-1-carboxylate.
Ester 254 (383 mg, 0.970 mmol) was dissolved in DCM (5 mL) in a 20 mL vial in open air
with stir bar, and Pd(OH)2/C (20%) (34 mg, 0.048 mmol) and K2CO3 (33.5 mg, 0.242
mmol) were added. The mixture was cooled in an ice bath to 4 °C and tbutylhydroperoxide (TBHP) (0.66 mL, 4.85 mmol) was added with vigorous stirring. The
vial was sealed and allowed to warm up to rt. The reaction mixture was stirred at 24 °C for
48 h, after which time TLC (3% EtOAc/hexanes) showed incomplete consumption of
starting material. More t-BuOOH (0.1 mL), Pd(OH)2/C (20%) (10 mg), and K2CO3 (30 mg)
were added, and after another 48 h, TLC showed a small amount of starting material
remaining. Another portion of t-BuOOH (0.2 mL) was added, the mixture was stirred for
another 2 h, then the solution was diluted with DCM and passed through a pipette packed
with silica gel and Na2SO4, eluted with additional DCM. The resulting solution was
concentrated to give a colorless oil, which was purified by column chromatography on a
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25 g column (EtOAc/hexanes, 0–20%) to give 255 (196 mg, 50%) as a colorless oil. Rf =
0.1 (5% EtOAc/hexanes). 1H NMR (400 MHz, CDCl3) δ 7.69 – 7.51 (m, 4H), 7.44 – 7.33
(m, 6H), 6.82 (d, J = 1.6 Hz, 1H), 3.96 (dd, J = 10.0, 3.8 Hz, 1H), 3.89 – 3.80 (m, 1H),
3.76 (s, 3H), 3.41 – 3.30 (m, 1H), 2.64 – 2.58 (m, 2H), 0.99 (s, 9H); 13C NMR (101 MHz,
CDCl3) δ 208.2, 164.4, 163.2, 139.7, 135.5, 133.0, 132.9, 129.8, 129.8, 127.8, 127.7, 127.7,
63.4, 52.3, 42.5, 40.0, 26.7, 26.7, 19.2. IR (thin film): ν = 2931, 2857, 1719, 1215, 1104,
821, 699 cm-1. HRMS (ESI+) calcd for C24H29O4Si [M+H] 409.1835, found 409.1828.

(5-(((tert-butyldiphenylsilyl)oxy)methyl)-3-hydroxycyclopent-1-en-1-yl)methyl
acetate. Enone 255 (7.20 g, 17.6 mmol) was added to a 1 L round bottom flask with stir
bar and sealed with a septum under nitrogen. Anhydrous toluene (200 mL) was added by
syringe, and the resulting solution was cooled to –40 oC. DIBAL (1.2M solution in toluene,
45.5 mL, 54.6 mmol) was added, and the mixture was stirred for 10 min, after which time
TLC (5% EtOAc/hexanes) indicated complete consumption of the starting material.
Saturated potassium sodium tartrate solution (300 mL) was added to quench the reaction
at the same temperature, followed by EtOAc (300 mL). The mixture was stirred at rt for 24
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h, then the organic phase was separated and the aqueous phase was extracted with EtOAc
(3 x 100 mL). The combined organics were dried over Na2SO4, filtered, and concentrated
to give the crude diol intermediate as a colorless oil. This was sealed under nitrogen and
dissolved in pyridine (200 mL), then the mixture was cooled to –20 oC and acetic anhydride
(1.95 mL, 20.7 mmol) was added. The reaction was stirred at –20 oC for 24 h, after which
time TLC analysis indicated that the reaction was incomplete (5% EtOAc/hexanes).
Another portion of acetic anhydride (0.85 mL, 9.0 mmol) was added after 24 h, another
portion (0.35 mL, 3.7 mmol) was added after 48 h, another portion (0.10 mL, 1.1 mmol)
was added after 72 h, and smaller portions (0.05 mL, 0.53 mmol) were added after 96 h,
120 h, and 144 h until the starting material was consumed. The reaction mixture was
concentrated to a yellow oil and purified by flash chromatography on a 100 g column
(EtOAc/hexanes, 20–40%) to give 256 (3.68 g, 50%) as a yellow oil, which was an
inconsequential mixture of diastereomers. Rf1= 0.15, Rf2= 0.1 (20% EtOAc/hexanes). 1H
NMR (400 MHz, CDCl3) δ 7.72 – 7.53 (m, 4H), 7.49 – 7.28 (m, 6H), 5.96 (s, 1H), 4.71 –
4.42 (m, 1H), 3.71 – 3.54 (m, 2H), 2.82 – 2.56 (m, 2H), 2.44 (ddd, J = 14.2, 8.9, 7.0 Hz,
1H), 2.03 (s, 3H), 1.74 (dt, J = 14.1, 2.1 Hz, 1H), 1.06 (s, 9H). 13C NMR (101 MHz, CDCl3)
δ 170.6, 142.6, 135.7, 135.6, 132.7, 132.6, 132.3, 130.0, 129.9, 127.8, 74.8, 64.3, 61.6,
46.2, 38.1, 26.9, 20.8, 19.2. IR (thin film): ν = 3435, 2930, 2857, 1739, 1222, 1110, 1017,
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699 cm-1. HRMS (ESI+) calcd for C25H32NaO4Si [M+Na] 447.1968, found 447.1967.

(5-(((tert-butyldiphenylsilyl)oxy)methyl)-3-oxocyclopent-1-en-1-yl)methyl

acetate.

Alcohol 256 (3.68 g, 8.67 mmol) was added to a 500 mL round bottom flask with stir bar
and dissolved with DCM (200 mL). Silica gel (5.6 g) was added, followed by PCC (5.6 g,
26 mmol). The mixture was stirred for 1 h, after which time TLC (20% EtOAc/hexanes)
indicated complete consumption of the starting material. The mixture was loaded directly
onto a 25 g silica gel column and purified by column chromatography (100% DCM, then
10–25% EtOAc/hexanes) to give 257 (3.05 g, 83%) as a yellow oil. Rf = 0.2 (20%
EtOAc/hexanes). 1H NMR (400 MHz, CDCl3) δ 7.69 – 7.56 (m, 4H), 7.49 – 7.35 (m, 6H),
6.15 (q, J = 1.7 Hz, 1H), 5.02 (dd, J = 17.2, 1.8 Hz, 1H), 4.84 (d, J = 17.2 Hz, 1H), 3.77
(dd, J = 10.3, 4.7 Hz, 1H), 3.70 (dd, J = 10.3, 6.0 Hz, 1H), 3.15 – 2.99 (m, 1H), 2.52 (dd,
J = 18.5, 6.9 Hz, 1H), 2.25 (dd, J = 18.6, 2.3 Hz, 1H), 2.12 (d, J = 0.6 Hz, 3H), 1.04 (s,
9H). 13C NMR (101 MHz, CDCl3) δ 207.1, 175.2, 170.2, 135.5, 132.8, 132.7, 130.3, 130.0,
130.0, 127.9, 64.5, 62.7, 43.7, 38.7, 26.8, 20.7, 19.2. IR (thin film): ν = 2930, 2857, 1744,
1715, 1427, 1220, 1105, 701 cm-1. HRMS (ESI+) calcd for C25H31O4Si [M+H] 423.1992,
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found 423.1988.
4.2 Construction of Quaternary Center at C-2 Bicyclo[2.2.1]heptane
Core

Tert-butyl((3,3-dimethylcyclopenta-1,4-dien-1-yl)oxy)dimethylsilane. To a solution of
26679 (302 mg, 2.742 mmol) in acetonitrile (4 mL) were added triethylamine (0.57 mL,
4.112 mmol), tert-butyldimethylsilyl chloride (619.8 mg, 4.112 mmol) and NaI (616.4 mg,
4.112 mmol) in this order. The reaction mixture was stirred overnight at room temperature,
after which point GC-MS indicated complete consumption of the starting material and the
desired mass of the desired product, PE (5 mL) and saturated NaHCO3 solution (5 mL)
were added. The layers were separated and the combined acetonitrile–water phases were
extracted with PE 3 x 5 mL. The combined organic layers were washed with brine, dried
over Na2SO4 and evaporated under reduced pressure. The residue was dissolved in hexane
and eluted through an Al2O3 (pH= 9.0) packed pipette, concentrated to give 262 a colorless
oil, 615 mg, 93%. 1H NMR (400 MHz, Acetone-d6) δ 6.14 (dd, J = 5.4, 2.4 Hz, 1H), 5.87
(dd, J = 5.4, 1.7 Hz, 1H), 5.09 (dd, J = 2.4, 1.7 Hz, 1H), 1.09 (s, 6H), 0.89 (s, 9H), 0.12 (s,
6H).
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2-(2,4-difluorophenyl)acrylonitrile.

A

solution

of 2-(2,4-

difluorophenyl)acetonitrile (0.1 mL, 0.82 mmol), paraformaldehyde (37.5 mg, 1.25 mmol),
K2CO3 (1.18 g, 1.31 mmol) and Bu4NI (6 mg, 16 umol) in toluene (2 mL) was stirred under
nitrogen atmosphere in a 20 mL vial sealed with septum at 80 °C for 5h, TLC indicated
complete consumption of the starting material, The reaction mixture was poured into a
saturated aqueous solution of NaCl (5 mL) and then extracted with EtOAc (3 x 10 mL).
The organic layer was dried over Na2SO4 and concentrated in vacuo. The crude sample
was purified by chromatography 0-15% EtOAc/Hexane to give 267 as a yellow oil, 2.5 mg,
2% yield. 1H NMR (400 MHz, Chloroform-d) δ 7.56 (td, J = 8.9, 6.3 Hz, 1H), 7.04 – 6.76
(m, 2H), 6.45 (d, J = 0.5 Hz, 1H), 6.32 (dd, J = 2.1, 0.6 Hz, 1H).

3-(2-phenylacryloyl)oxazolidin-2-one. 2-phenylacrylic acid (1 g, 6.75 mmol),
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oxazolidin-2-one (705 mg, 8.1 mmol) and DMAP (124 mg, 1.01 mmol) was dissolved in
DCM (20 mL) in a 100 mL round bottom flask, DIC (3.6 mL,22.9 mmol) was added, the
mixture was stirred at rt for 24h, TLC indicated the starting material was completely
consumed, the suspension was then filtered through a Celite packed sintered glass,
concentrated and purified by chromatography 0-50% EtOAc/Hexane to give 270 as a white
solid, 638 mg, 44% yield. 1H NMR (400 MHz, Chloroform-d) δ 7.44 – 7.29 (m, 4H), 5.81
(d, J = 0.8 Hz, 1H), 5.56 (d, J = 0.8 Hz, 1H), 4.52 – 4.36 (m, 2H), 4.13 (tt, J = 7.9, 0.7 Hz,
2H). Product previously characterized in the literature.103

((4aS,5S)-7a-((tert-butyldimethylsilyl)oxy)-5-(((tert-butyldiphenylsilyl)oxy)methyl)3-(2,4-difluorophenyl)-4,4a,5,7a-tetrahydrocyclopenta[b]pyran-6-yl)methyl acetate.
To a solution of enal 274 (49.7 mg, 0.296 mmol) in DCM (2.7 mL) was added
cyclopentadiene 258 (94.6 mg, 176 µmol) in DCM (3 mL), and the mixture was stirred at
rt for 24 h. TLC (10% EtOAc/hexanes) indicated complete consumption of the starting
material, so the mixture was concentrated and purified on a 10g SiO2 column (30%
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DCM/hexanes) to give 276 (64.2 mg, 52%) as a yellow oil. 1H NMR (300 MHz, acetoned6) δ 7.76 – 7.60 (m, 4H), 7.52 – 7.33 (m, 6H), 7.26 (td, J = 9.0, 6.6 Hz, 1H), 7.06 – 6.90
(m, 2H), 6.78 (d, J = 1.7 Hz, 1H), 5.93 (d, J = 1.8 Hz, 1H), 4.77 (qt, J = 14.7, 1.4 Hz, 2H),
3.89 (dd, J = 10.7, 4.4 Hz, 1H), 3.80 (dd, J = 10.7, 4.7 Hz, 1H), 2.83 (s, 1H), 2.74 – 2.61
(comp, 3H), 2.03 (s, 3H), 1.05 (s, 9H), 0.91 (s, 9H), 0.22 (s, 3H), 0.16 (s, 3H). 13C NMR
(75 MHz, acetone-d6) δ 170.7, 144.8, 144.0, 143.9, 136.5, 136.4, 134.3, 134.1, 132.0, 130.9,
130.9, 130.8, 130.7, 128.9, 128.8, 112.3, 107.7, 105.2, 104.9, 64.1, 62.4, 50.3, 46.9, 27.4,
26.2, 23.6, 20.8, 20.0, 18.5, –2.8. Decomposed to give 277 under LC-MS conditions
(formic acid/MeOH).

((4S,5S)-5-(((tert-butyldiphenylsilyl)oxy)methyl)-4-(2-(2,4-difluorophenyl)-3oxopropyl)-3-oxocyclopent-1-en-1-yl)methyl acetate. To a solution of 276 (9.9 mg, 14
µmol) in MeOH (1 mL) in a 4 mL vial was added formic acid (50 µL, 1.2 mmol). After 5
min., TLC (10% EtOAc/hexanes) indicated complete consumption of 276, so the reaction
mixture was concentrated and purified by chromatography on a silica gel packed pipette
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(10–20% EtOAc/hexanes) to give aldehyde 277 (1:1 diastereomeric mixture, 6.0 mg, 73%)
as a colorless oil. 1H NMR (400 MHz, CDCl3) δ 9.62 (d, J = 1.4 Hz, 1H), 9.58 (t, J = 1.0
Hz, 1H), 7.66 – 7.49 (comp, 8H), 7.48 – 7.33 (comp, 12H), 7.25 – 7.15 (m, 1H), 7.02 (td,
J = 8.5, 6.2 Hz, 1H), 6.89 – 6.74 (comp, 4H), 6.11 (q, J = 1.7 Hz, 1H), 6.06 (q, J = 1.7 Hz,
1H), 5.01 (d, J = 17.2 Hz, 1H), 4.92 (d, J = 17.4 Hz, 1H), 4.83 – 4.73 (m, 2H), 4.27 (dd, J
= 9.4, 5.3 Hz, 1H), 3.95 (dd, J = 8.2, 5.6 Hz, 1H), 3.77 (dd, J = 10.4, 4.0 Hz, 1H), 3.64 (dd,
J = 10.5, 6.2 Hz, 1H), 3.59 (d, J = 5.0 Hz, 3H), 2.73 – 2.58 (m, 3H), 2.38 (ddd, J = 13.9,
9.9, 5.3 Hz, 1H), 2.21 – 2.14 (m, 2H), 2.13 (s, 3H), 2.11 (s, 3H), 2.05 – 1.94 (m, 1H), 1.84
(ddd, J = 14.5, 9.4, 5.6 Hz, 1H), 1.01 (s, 9H), 0.97 (d, J = 2.6 Hz, 9H). HRMS (ESI+): calcd
for C34H36F2NaO5Si [M+Na]+ 613.2198; found 613.2207.

Methyl

1-(acetoxymethyl)-5-((tert-butyldimethylsilyl)oxy)-7-(((tert-

butyldiphenylsilyl)oxy)methyl)-2-(trifluoromethyl)bicyclo[2.2.1]hept-5-ene-2carboxylate. To a solution of cyclopentadiene 258 (10 mg, 19 µmol) in DCM (0.4 mL)
was added methyl 2-(trifluoromethyl)acrylate (278) (4.6 µL, 37 µmol) in 1 mL DCM, and
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the mixture was stirred at rt for 24 h. TLC indicated complete consumption of the starting
material (20% EtOAc/hexanes), so the mixture was concentrated and purified by
chromatography on a Pasteur pipette packed with silica gel (4% EtOAc/hexanes) to give
cycloadduct 279 (1:1.4 diastereomeric mixture, 5.2 mg, 40%) as a yellow oil. 1H NMR
(400 MHz, CDCl3) δ 7.67 – 7.55 (comp, 6H), 7.46 – 7.32 (comp, 8H), 4.56 – 4.02 (comp,
5H), 3.76 (s, 3H), 3.71 (s, 2H), 3.63 (dd, J = 10.2, 5.0 Hz, 1H), 3.51 (dd, J = 10.1, 5.0 Hz,
1H), 2.92 – 2.76 (m, 3H), 2.59 (d, J = 13.0 Hz, 1H), 2.50 (ddd, J = 21.3, 9.2, 5.0 Hz, 2H),
2.19 (dd, J = 12.9, 3.5 Hz, 1H), 1.91 (d, J = 12.5 Hz, 1H), 1.77 (d, J = 2.0 Hz, 6H), 1.03
(d, J = 4.3 Hz, 18H), 0.93 (d, J = 3.1 Hz, 18H), 0.16 (d, J = 7.6 Hz, 5H), 0.12 (d, J = 13.8
Hz, 4H).

19

F NMR (376 MHz, CDCl3) δ –61.52, –64.24.

13

C NMR (75 MHz, CDCl3) δ

170.7, 170.3, 169.8, 169.0, 162.6, 162.3, 135.7, 135.6, 133.9, 133.8, 133.8, 133.7, 129.7,
127.8, 99.6, 97.4, 62.9, 62.6, 61.8, 61.1, 60.5, 60.0, 59.5, 58.4, 52.9, 52.9, 47.4, 46.4, 34.6,
34.5, 27.0, 25.7, 20.6, 19.4, 18.1, 0.2, –4.5, –4.6. HRMS (ESI+): calcd for C36H50F3O6Si2
[M+H] 691.3098; found 691.3111.
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7-(((tert-butyldiphenylsilyl)oxy)methyl)-1-((methoxymethoxy)methyl)-5methylenebicyclo[2.2.1]heptane-2-carbonitrile. To a solution of 302 (110 mg, 0.254
mmol) in CHCl3 (5 mL) was added dimethoxymethane (224 µL, 2.54 mmol) and P2O5 (500
mg, 1.76 mmol).104 The mixture was sealed under N2 and stirred for 10 min. TLC (20%
EtOAc/hexanes) indicated complete consumption of the starting material, the mixture was
filtered through Celite and concentrated, and

the intermediate MOM ether was used

directly in the next step. To a solution of methyltriphenylphosphonium bromide (272 mg,
0.762 mmol) in toluene (5 mL) sealed under N2 was added KHMDS (0.5 M in toluene,
1.52 mL, 0.762 mmol). The mixture was heated to 90 ºC for 30 min., then the intermediate
MOM ether was added (in toluene, 5 mL). The mixture was stirred at 90 ºC for 10 min.,
after which time TLC (40% EtOAc/hexanes) indicated complete consumption of the
starting material. The mixture was filtered through Celite, concentrated, and loaded as a
toluene solution onto a 10 g SiO2 column, and purified by chromatography (5–10%
EtOAc/hexanes) to give alkene 298 (1:0.7 diastereomeric mixture, 75 mg, 62%) as a
colorless oil. 1H NMR (300 MHz, CDCl3) δ 7.73 – 7.58 (comp, 7H), 7.49 – 7.31 (comp,
10H), 4.98 (t, J = 2.5 Hz, 1H), 4.93 – 4.87 (m, 1H), 4.80 (s, 1H), 4.71 (s, 1H), 4.65 – 4.57
(m, 1H), 4.57 – 4.49 (m, 2H), 3.90 (d, J = 10.1 Hz, 1H), 3.73 (d, J = 10.1 Hz, 1H), 3.70 –
3.61 (m, 1H), 3.59 – 3.43 (comp, 4H), 3.35 (s, 2H), 3.24 (s, 3H), 3.09 (ddd, J = 12.0, 5.0,
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2.5 Hz, 1H), 2.85 (d, J = 4.3 Hz, 1H), 2.75 (q, J = 5.8, 5.2 Hz, 1H), 2.47 (dd, J = 17.1, 2.1
Hz, 1H), 2.28 (dd, J = 12.3, 4.3 Hz, 1H), 2.23 – 1.96 (comp, 5H), 1.89 (dd, J = 12.6, 9.4
Hz, 1H), 1.69 (dd, J = 12.5, 5.0 Hz, 1H), 1.05 (s, 6H), 1.03 (s, 9H). 13C NMR (75 MHz,
CDCl3) δ 150.3, 149.5, 135.7, 135.7, 135.7, 135.6, 133.6, 133.5, 133.4, 133.2, 129.9, 129.8,
127.9, 127.8, 127.8, 127.8, 121.5, 121.1, 107.1, 106.6, 96.9, 96.6, 69.4, 66.3, 61.1, 61.1,
55.5, 55.4, 53.1, 52.9, 52.8, 47.6, 38.0, 35.4, 34.9, 34.5, 33.7, 32.4, 26.9, 19.3, 19.3. HRMS
(ESI+): calcd for C29H37NNaO3Si [M+Na]+ 498.2440; found 498.2452.

4.3 Endgame Synthesis

4.3.1

1st Generation Endgame Synthesis of Bicyclic Sordarin
Analog

3-((tert-butyldimethylsilyl)oxy)-7-(((tert-butyldiphenylsilyl)oxy)methyl)-6cyanobicyclo[2.2.1]hept-2-en-1-yl)methyl acetate. A 0.096 M solution of enone 257 in
DCM (12.0 mL, 1.16 mmol) in a 50 mL round bottom flask with stir bar was sealed under
nitrogen and cooled to –20 oC. NEt3 (235 µL, 1.69 mmol) and TBSOTf (337 µL, 1.47
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mmol) were added, and the reaction was gradually warmed up to 15 oC over 3 h. The
mixture was then quenched with aqueous phosphate buffer (10 mL, pH 7), the organic layer
was separated, and the aqueous layer was then extracted with DCM (3 x 10 mL). The
combined organics were dried over Na2SO4, filtered, and concentrated to an oil, then the
desired product was extracted with hexanes and re-concentrated to give the crude diene 15,
which was used directly in the next step. Diene 15 was dissolved in DCM (10 mL) and
acrylonitrile (passed through a column of basic alumina before use; 4.05 mL, 61.9
mmol) was added. The reaction was stirred at rt for 24 h, after which time TLC (20%
EtOAc/hexanes) indicated complete consumption of the starting material. The mixture was
concentrated to give crude 300 as a racemic, ~1:1 mixture of endo/exo diastereomers, and
the yellow oil was used directly in the next step. 1H NMR (400 MHz, CDCl3) δ 7.63 (dddt,
J = 11.2, 8.1, 3.3, 1.4 Hz, 4H), 7.48 – 7.32 (m, 6H), 4.66 – 4.24 (m, 3H), 3.84 – 3.47 (m,
2H), 2.99 (dd, J = 9.4, 4.1 Hz, 1H), 2.73 – 2.50 (m, 2H), 2.37 – 2.09 (m, 2H), 1.98 – 1.77
(m, 1H), 1.64 (dd, J = 12.6, 3.8 Hz, 1H), 1.16 – 0.98 (m, 9H), 0.98 – 0.80 (m, 9H), 0.26 –
0.05 (m, 6H).
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C NMR (101 MHz, CDCl3) δ 170.9, 170.8, 162.0, 161.7, 135.7, 135.6,

135.6, 133.5, 133.4, 133.4, 129.9, 129.8, 129.8, 127.9, 127.9, 127.8, 122.1, 121.5, 99.8,
97.9, 64.5, 63.6, 61.1, 61.1, 60.1, 59.6, 58.1, 57.7, 48.5, 48.1, 34.3, 34.2, 33.5, 33.4, 26.9,
26.9, 25.8, 25.8, 25.7, 25.7, 25.7, 20.9, 20.8, 19.3, 19.3, 18.1. IR (thin film): ν = 2930, 2857,
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2234, 1744, 1616, 1227, 871, 701 cm-1. HRMS (ESI+) calcd for C34H47NNaO4Si2 [M+Na]
612.2941, found 612.2922.

7-(((tert-butyldiphenylsilyl)oxy)methyl)-1-(hydroxymethyl)-5oxobicyclo[2.2.1]heptane-2-carbonitrile. The enolsilane 300 (682 mg, 1.16 mmol) was
added to a 25 mL round bottom flask with stir bar and sealed under nitrogen, then CHCl3
(10 mL) was added, and the solution was cooled in a bath at –10 oC. Boron trifluoride
etherate (purified by distillation prior to use; 214 µL, 1.73 mmol) was added and the
solution was warmed up to 0 oC over 30 min., after which time TLC (20% EtOAc/hexanes)
indicated complete consumption of starting material. The mixture was quenched with sat.
aq. NaHCO3 (5 mL), then the layers were separated and the aqueous layer re-extracted with
DCM (3 x 5 mL). The combined organics were dried over Na2SO4, filtered, and
concentrated, to give the crude ketone product (61.8 mg, 0.13 mmol). This was dissolved
with MeOH (5 mL), and K2CO3 (18 mg, 0.13 mmol) was added. The mixture was stirred
at rt for 30 min., after which time TLC (20% EtOAc/hexanes) indicated complete
consumption of starting material. The mixture was passed through a plug of silica gel in a
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Pasteur pipette, concentrated, and then repurified by column chromatography using a
Pasteur pipette packed with silica gel (EtOAc/hexanes, 21–27%) to give 302a (20.3 mg,
24% over 4 steps), Rf = 0.5 (40% EtOAc/hexanes) and 302b (21.4 mg, 25%), Rf = 0.38
(40% EtOAc/hexanes), both as colorless oils. 302a (endo): 1H NMR (400 MHz, CDCl3) δ
7.68 – 7.57 (m, 4H), 7.51 – 7.34 (m, 6H), 3.95 – 3.79 (m, 2H), 3.66 (dd, J = 11.5, 4.2 Hz,
1H), 3.54 (dd, J = 11.4, 9.9 Hz, 1H), 3.17 (ddd, J = 11.8, 5.5, 2.1 Hz, 1H), 3.04 (t, J = 6.7
Hz, 1H), 2.47 – 2.29 (m, 4H), 2.17 (dd, J = 9.9, 4.1 Hz, 1H), 1.85 – 1.75 (m, 1H), 1.06 (s,
9H).
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C NMR (101 MHz, CDCl3) δ 211.7, 135.6, 135.6, 132.0, 131.8, 130.49, 130.45,

128.23, 128.20, 120.1, 61.5, 61.2, 54.2, 51.8, 51.6, 38.6, 31.6, 29.2, 26.89, 26.86, 19.1. IR
(thin film): ν = 3458, 2931, 2858, 2239, 1751, 1427, 1112, 738, 702 cm-1. HRMS (ESI+)
calcd for C26H31NNaO3Si [M+Na] 456.1971, found 456.1974. 302b (exo): 1H NMR (400
MHz, CDCl3) δ 7.64 (ddt, J = 14.8, 7.9, 1.3 Hz, 4H), 7.51 – 7.35 (m, 6H), 4.15 (dd, J =
11.6, 3.0 Hz, 1H), 3.91 (dd, J = 11.9, 8.5 Hz, 1H), 3.67 (dd, J = 11.6, 4.6 Hz, 1H), 3.62 –
3.51 (m, 1H), 3.33 (dd, J = 8.6, 3.6 Hz, 1H), 2.77 (dd, J = 9.2, 4.6 Hz, 1H), 2.70 (d, J =
18.9 Hz, 1H), 2.44 (d, J = 4.9 Hz, 1H), 2.36 – 2.28 (m, 1H), 2.19 (dt, J = 13.8, 4.8 Hz, 1H),
2.03 (dd, J = 13.8, 9.3 Hz, 1H), 1.93 (dd, J = 18.9, 2.5 Hz, 1H), 1.06 (s, 9H). 13C NMR (75
MHz, CDCl3) δ 212.4, 135.7, 135.6, 132.0, 132.0, 130.4, 130.3, 128.2, 128.2, 120.3, 62.9,
60.9, 53.2, 52.2, 51.9, 41.7, 33.8, 29.9, 26.9, 19.2.
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7-(((tert-butyldiphenylsilyl)oxy)methyl)-5-oxo-1-(((tetrahydro-2H-pyran-2yl)oxy)methyl)bicyclo[2.2.1]heptane-2-carbonitrile. To a solution of alcohol 302a (34.6
mg, 0.0798 mmol) and 3,4-dihydro-2H-pyran (36.4 µL, 0.40 mmol) in DCM (1 mL) in a
8 mL vial, was added a spatula tip of pyridinium p-toluenesulfonate (unweighed, ~1 mg).
The mixture was stirred at rt for 1.5 h, after which time TLC indicated complete
consumption of starting material (40% EtOAc/hexanes). The reaction mixture was loaded
directly onto a silica gel packed pipette and purified by column chromatography
(EtOAc/hexanes, 10–15%) to give THP acetal 303 as a mixture of diastereomeric acetals
(38.1 mg, 92%). Rf = 0.36 (20% EtOAc/hexanes). 1H NMR (400 MHz, CDCl3) δ 7.67 –
7.56 (m, 8H), 7.49 – 7.33 (m, 12H), 4.62 – 4.53 (m, 1H), 4.51 – 4.48 (m, 1H), 3.96 (d, J =
10.6 Hz, 1H), 3.86 (d, J = 10.6 Hz, 1H), 3.83 – 3.68 (m, 3H), 3.66 – 3.47 (m, 5H), 3.44 (d,
J = 10.6 Hz, 1H), 3.38 (dt, J = 11.1, 4.4 Hz, 1H), 3.19 (dddd, J = 19.5, 11.7, 5.4, 2.1 Hz,
2H), 2.78 (dd, J = 23.0, 4.9 Hz, 2H), 2.49 – 2.24 (m, 6H), 2.18 – 2.09 (m, 2H), 1.82 (dt, J
= 13.6, 4.9 Hz, 2H), 1.78 – 1.35 (m, 14H), 1.02 (d, J = 1.2 Hz, 18H). 13C NMR (101 MHz,
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CDCl3) δ 212.0, 211.9, 135.6, 132.8, 132.7, 130.0, 130.0, 130.0, 130.0, 127.9, 127.9, 127.9,
120.3, 120.3, 98.9, 98.8, 65.7, 65.6, 62.1, 62.0, 60.8, 60.6, 52.0, 51.9, 51.9, 51.9, 51.4, 51.4,
40.4, 40.2, 32.1, 31.9, 30.3, 30.2, 29.1, 26.8, 26.8, 25.4, 25.3, 19.2, 19.2, 19.1. IR (thin
film): 2938, 2858, 2239, 1753, 1111, 1030, 905, 701. HRMS (ESI+) calcd for
C31H39NNaO4Si [M+Na] 540.2546, found 540.2527.

7-(((tert-butyldiphenylsilyl)oxy)methyl)-5-methylene-1-(((tetrahydro-2H-pyran-2yl)oxy)methyl)bicyclo[2.2.1]heptane-2-carbonitrile. Ph3PMeBr (76.6 mg, 0.214 mmol)
was added to an 8 mL vial with stir bar and sealed with a septum under nitrogen. Anhydrous
toluene (1 mL) was added, followed by 0.5 M KHMDS in toluene (0.429 mL, 0.214 mmol)
at rt. The yellow solution was heated at 90 oC for 30 min, during which time it became a
yellow slurry. Ketone 303 (37 mg, 0.072 mmol) in toluene (1 mL) was added, and the
mixture was stirred at 90 oC for 30 min., after which time TLC analysis indicated that the
ketone was consumed (20% EtOAc/hexanes). The mixture was loaded directly onto a silica
gel packed pipette and purified (EtOAc/hexanes, 5–15%) to give alkene 304 (34.2 mg,
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93%) as a colorless oil (THP diastereomers). Rf = 0.65 (20% EtOAc/hexanes). 1H NMR
(400 MHz, CDCl3) δ 7.64 (ddt, J = 8.1, 5.0, 1.9 Hz, 8H), 7.50 – 7.31 (m, 12H), 4.99 (dt, J
= 14.4, 2.6 Hz, 2H), 4.80 (d, J = 7.7 Hz, 2H), 4.55 (dt, J = 12.6, 3.1 Hz, 2H), 3.86 (d, J =
10.4 Hz, 1H), 3.77 – 3.56 (m, 5H), 3.53 – 3.31 (m, 6H), 3.05 (dddd, J = 22.0, 12.0, 5.0, 2.5
Hz, 2H), 2.90 (d, J = 4.2 Hz, 1H), 2.80 (d, J = 4.2 Hz, 1H), 2.52 (dd, J = 4.0, 2.0 Hz, 1H),
2.48 (dd, J = 3.9, 2.0 Hz, 1H), 2.26 (tdd, J = 12.4, 4.5, 1.7 Hz, 2H), 2.11 (d, J = 2.8 Hz,
1H), 2.07 (d, J = 2.9 Hz, 1H), 2.04 – 1.95 (m, 2H), 1.81 – 1.38 (m, 16H), 1.03 (d, J = 1.4
Hz, 18H). 13C NMR (101 MHz, CDCl3) δ 149.8, 149.7, 135.7, 135.7, 135.6, 129.8, 129.8,
127.8, 127.8, 127.7, 107.1, 107.0, 98.6, 98.5, 66.5, 66.4, 61.7, 61.6, 61.4, 61.1, 53.2, 53.1,
52.9, 47.7, 47.7, 34.7, 34.6, 33.9, 33.7, 32.7, 32.7, 30.3, 26.9, 25.6, 25.5, 19.3, 19.3, 19.1,
18.9. HRMS (ESI+) calcd for C32H41NNaO3Si [M+Na] 538.2753, found 538.2743.

5-methylene-7-((pentyloxy)methyl)-1-(((tetrahydro-2H-pyran-2yl)oxy)methyl)bicyclo[2.2.1]heptane-2-carbonitrile. To a solution of 304 (16.0 mg,
0.058 mmol) in THF was added TBAF 1M solution in THF (29 µL, 0.029 mmol), the
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mixture was stirred for 30 min, concentrated and dissolved in EtOAc (2 mL), washed with
1M HCl (2 mL), dried over Na2SO4 and concentrated to give a crude residue. This crude
reside was dissolved in DMF (0.5 mL) in a 20 mL vial, NaH (~5 mg) was added at 0 oC, the
ice bath was removed, and 1-iodopentane (15.1 µL, 0.115 mmol) was added. The mixture
was stirred at rt for 2 h, after which time TLC (50% EtOAc/hexanes) indicated complete
consumption of the stating material. The reaction was quenched with water (5 mL)
and extracted with EtOAc (3 x 5 mL). The combined organics were washed with water (2
x 5 mL) and brine (5 mL), dried over Na2SO4, filtered, and concentrated to give a crude
yellow oil. The crude was purified by column chromatography on a silica gel packed
pipette (10% EtOAc/hexanes) to give ether 305 (13.1 mg, 65%) as a colorless oil (THP
diastereomers). Rf = 0.2 (10% EtOAc/Hexane). 1H NMR (400 MHz, CDCl3) δ 4.99 (dd, J
= 7.4, 2.6 Hz, 1H), 4.84 – 4.77 (m, 1H), 4.64 (q, J = 3.6 Hz, 1H), 3.93 – 3.75 (m, 2H), 3.60
– 3.48 (m, 1H), 3.48 – 3.29 (m, 4H), 3.26 – 3.14 (m, 1H), 3.08 (dddd, J = 17.1, 12.0, 5.0,
2.6 Hz, 1H), 2.74 (dd, J = 24.3, 4.3 Hz, 1H), 2.53 (dt, J = 17.1, 2.1 Hz, 1H), 2.23 (tdd, J =
12.3, 4.4, 2.7 Hz, 1H), 2.17 – 2.07 (m, 1H), 2.02 – 1.94 (m, 1H), 1.81 (ddt, J = 11.2, 8.2,
4.7 Hz, 1H), 1.71 – 1.46 (m, 9H), 1.36 – 1.21 (m, 5H), 0.93 – 0.84 (m, 3H). 13C NMR (101
MHz, CDCl3) δ 149.9, 149.8, 121.6, 107.0, 106.8, 99.0, 98.7, 71.7, 71.6, 68.1, 67.8, 66.4,
66.2, 61.9, 61.8, 53.3, 53.1, 50.6, 50.3, 47.9, 47.9, 34.6, 34.5, 33.9, 33.7, 32.4, 32.4, 30.5,
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30.4, 29.5, 29.4, 28.4, 28.4, 25.6, 25.5, 22.6, 22.6, 19.2, 19.1, 14.2. HRMS (ESI+) calcd for
C21H33NNaO3 [M+Na] 370.2358, found 370.2353.

1-(hydroxymethyl)-5-methylene-7-((pentyloxy)methyl)bicyclo[2.2.1]heptane-2carbonitrile. To a solution of THP acetal 305 (12.0 mg, 34.5 µmol) in MeOH (1 mL) in a
4 mL vial was added Amberlyst® 15 (50.0 mg). The mixture was stirred at 60 oC for 45
min., after which time TLC (10% EtOAc/hexanes) indicated complete consumption of the
starting material. The solution was decanted and concentrated to give a crude residue,
which was purified by column chromatography (EtOAc/hexanes, 15–20%) to give alcohol
325 (7.8 mg, 86%) as a colorless oil. Rf = 0.22 (20% EtOAc/hexanes). 1H NMR (400 MHz,
CDCl3) δ 4.94 (t, J = 2.6 Hz, 1H), 4.78 (s, 1H), 3.69 (d, J = 7.0 Hz, 2H), 3.48 – 3.38 (m,
3H), 3.35 – 3.23 (m, 2H), 2.97 (ddd, J = 12.0, 5.1, 2.4 Hz, 1H), 2.53 (d, J = 4.3 Hz, 1H),
2.41 (tdd, J = 20.0, 16.3, 2.3 Hz, 2H), 2.26 (td, J = 12.3, 4.4 Hz, 1H), 1.98 – 1.90 (m, 1H),
1.70 – 1.61 (m, 1H), 1.56 (t, J = 6.9 Hz, 2H), 1.30 (app tt, J = 5.8, 3.1 Hz, 4H), 0.89 (t, J =
6.8 Hz, 3H). 13C NMR (101 MHz, CDCl3) δ 150.3, 121.4, 106.4, 72.0, 68.8, 62.2, 56.0,
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50.9, 47.4, 34.8, 32.2, 32.1, 29.4, 28.3, 22.6, 14.1. HRMS (ESI+) calcd for C16H25NNaO2
[M+Na] 286.1783, found 286.1775.

2-cyano-5-methylene-7-((pentyloxy)methyl)bicyclo[2.2.1]heptane-1-carboxylic acid.
CrO3 (525 mg, 5.25 mmol) was dissolved in H2O (2 mL), and to the solution was added
conc. H2SO4 (0.45 mL), giving Jones reagent (2.5 mL). To a solution of 325 (7.5 mg, 29
µmol) in acetone (1 mL) in a 4 mL vial at 0 oC was added the solution of Jones reagent
(28.5 µL, 71.2 µmol). The yellow solution was stirred at 0 oC for 15 min., then at rt for 20
min., at which point the mixture was a green slurry. TLC showed complete consumption
of the starting material (20% EtOAc/hexanes). The reaction was quenched with MeOH (2
mL) and concentrated to give a green oil, which was purified by column chromatography
on a silica gel packed pipette (EtOAc/hexanes, 30–50%) to give acid 306 (6 mg, 76%) as
a colorless oil. Rf = 0.27 (50% EtOAc/hexanes with 2 drops of AcOH in 10 mL). 1H NMR
(400 MHz, CDCl3) δ 5.04 (t, J = 2.7 Hz, 1H), 4.91 (s, 1H), 3.49 – 3.33 (m, 5H), 2.84 (d, J
= 4.1 Hz, 1H), 2.80 (s, 2H), 2.37 (td, J = 12.3, 4.2 Hz, 1H), 2.30 (t, J = 7.2 Hz, 1H), 1.72
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(dd, J = 12.5, 4.9 Hz, 1H), 1.52 (p, J = 6.8 Hz, 2H), 1.34 – 1.15 (m, 5H), 0.88 (t, J = 6.8
Hz, 3H). 13C NMR (101 MHz, CDCl3) δ 176.6, 148.0, 120.3, 107.9, 71.9, 67.6, 56.5, 54.0,
48.6, 34.9, 34.3, 33.2, 29.2, 28.3, 22.6, 14.2. HRMS (ESI+) calcd for C16H24NO3 [M+H]
278.1756, found 278.1742.
4.3.2

4-methoxybenzyl

2nd Generation Endgame Synthesis of Bicyclic Sordarin
Analogs

7-(((tert-butyldiphenylsilyl)oxy)methyl)-2-cyano-5-

oxobicyclo[2.2.1]heptane-1-carboxylate. CrO3 (525 mg, 5.25 mmol) was dissolved in
H2O (2 mL). To the solution was added concentrated H2SO4 (0.45 mL), to give Jones
reagent (2.5 mL). To a solution of alcohol 302 (767 mg, 1.77 mmol) in acetone (20 mL) in
a 50 mL round bottom flask at 0 ºC was added Jones reagent (1.77 mL, 4.42 mmol), and
the mixture was stirred for 30 min. at rt. TLC (40% EtOAc/hexanes) showed complete
consumption of the starting material, so the mixture was quenched with MeOH (5 mL).
Na2SO4 was added and the mixture was filtered through Celite, and the mother liquor was
condensed to a green residue. The crude was dissolved in DCM (10 mL) and passed
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through a 10 g silica gel pad, eluting with 80% EtOAc/hexanes. The resulting eluent was
concentrated to give a crude yellow oil, which was dissolved in acetone (20 mL) in a 50
mL flask. To this solution was added PMBCl (360 µL, 2.65 mmol), K2CO3 (1.222 g, 8.84
mmol) and TBAI (13.1 mg, 0.0354 mmol). The mixture was stirred for 24h at rt, after
which time LC-MS indicated incomplete consumption of the starting material. Additional
PMBCl (0.200 mL, 1.47 mmol) was added, and the mixture was stirred for another 24 h,
after which time LC-MS showed complete conversion to the desired product. The mixture
was filtered through Celite, concentrated, and purified by chromatography on a 10 g SiO2
column (0–40% EtOAc/hexanes) to give ester 307 (388 mg, 39% over 3 steps) as a
colorless oil (1:1 diastereomeric mixture). 1H NMR (300 MHz, CDCl3) δ 7.67 – 7.51 (comp,
8H), 7.48 – 7.31 (comp, 12H), 7.19 (dd, J = 14.1, 8.7 Hz, 4H), 6.81 (dd, J = 8.7, 1.8 Hz,
4H), 5.18 – 4.92 (comp, 4H), 3.89 (dd, J = 11.3, 4.5 Hz, 1H), 3.78 (s, 6H), 3.60 (t, J = 6.2
Hz, 2H), 3.55 – 3.46 (m, 1H), 3.04 – 2.83 (comp, 4H), 2.82 – 2.75 (m, 2H), 2.69 – 2.59 (m,
2H), 2.46 (ddd, J = 13.7, 11.8, 4.9 Hz, 1H), 2.40 – 2.33 (m, 1H), 2.28 (dt, J = 13.8, 4.8 Hz,
1H), 2.16 – 2.06 (m, 2H), 1.79 (dd, J = 13.6, 5.4 Hz, 1H), 1.00 (d, J = 4.6 Hz, 18H). 13C
NMR (75 MHz, CDCl3) δ 209.8, 209.7, 169.6, 169.4, 159.9, 135.7, 135.6, 132.6, 132.5,
130.5, 130.2, 130.1, 130.0, 128.8, 128.0, 127.9, 127.0, 127.0, 119.9, 119.2, 114.2, 114.1,
67.7, 60.7, 60.5, 55.6, 55.4, 54.5, 52.4, 51.7, 51.3, 43.8, 39.7, 35.2, 33.9, 29.7, 29.0, 26.8,
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19.2. HRMS (ESI+): calcd for C34H37 NNaO5Si [M+Na]+ 590.2339; found 590.2352.

4-methoxybenzyl

7-(((tert-butyldiphenylsilyl)oxy)methyl)-2-cyano-5-

methylenebicyclo[2.2.1]heptane-1-carboxylate.

To

a

solution

of

methyltriphenylphosphonium bromide (18.9 mg, 0.0528 mmol) in dry toluene (1 mL)
sealed under N2 atmosphere was added KHMDS (0.5 M in toluene, 106 µL, 0.0528 mmol),
and the mixture was heated at 90 ºC for 30 min. To the reaction was added 42 (5.0 mg, 8.8
µmol) in toluene (0.5 mL), and the mixture was stirred for 10 min. at the same temperature.
TLC (20% EtOAc/hexanes) indicated complete consumption of the starting material, so
the mixture was filtered through Celite and concentrated, then purified by chromatography
on a silica gel packed pipette (5–10% EtOAc/hexanes) to give alkene 43 (4.7 mg, 94%) as
a colorless oil (1:1 diastereomeric mixture). 1H NMR (300 MHz, CDCl3) δ 7.68 – 7.53
(comp, 8H), 7.48 – 7.30 (comp, 12H), 7.17 (dd, J = 11.9, 8.7 Hz, 4H), 6.87 – 6.74 (comp,
4H), 5.14 – 4.90 (m, 6H), 4.82 (s, 1H), 4.78 (s, 1H), 3.99 (dd, J = 10.2, 4.6 Hz, 1H), 3.79
(d, J = 1.1 Hz, 6H), 3.66 (dd, J = 10.6, 6.2 Hz, 1H), 3.56 – 3.35 (m, 3H), 3.06 (d, J = 4.2
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Hz, 1H), 2.87 (d, J = 4.1 Hz, 1H), 2.83 (dd, J = 9.3, 5.1 Hz, 1H), 2.73 (s, 2H), 2.59 (dd, J
= 10.3, 4.6 Hz, 1H), 2.47 (d, J = 17.1 Hz, 1H), 2.35 (dd, J = 12.3, 4.2 Hz, 1H), 2.30 – 2.11
(m, 3H), 1.97 (dd, J = 12.6, 9.3 Hz, 1H), 1.69 (dd, J = 12.5, 5.0 Hz, 1H), 1.03 (s, 18H). 13C
NMR (75 MHz, CDCl3) δ 171.1, 171.0, 159.9, 148.3, 147.9, 135.8, 135.7, 133.6, 133.4,
130.4, 130.2, 130.0, 129.9, 129.8, 127.9, 127.9, 127.8, 127.5, 127.5, 121.1, 120.6, 114.2,
114.1, 107.8, 67.3, 61.1, 60.9, 56.9, 56.5, 56.5, 55.5, 53.0, 48.4, 47.5, 38.3, 36.0, 35.5, 34.8,
34.5, 33.5, 29.9, 27.0, 19.5, 19.4. HRMS (ESI+): calcd for C35H39NNaO4Si [M+Na]+
588.2546; found 588.2564.

4-methoxybenzyl

2-cyano-7-(hydroxymethyl)-2-methyl-5-

methylenebicyclo[2.2.1]heptane-1-carboxylate. To a solution of 308 (57.3 mg, 101
µmol) in toluene (1 mL), sealed under N2, was added iodomethane (63.0 µL, 1.01 mmol),
followed by KHMDS (0.5 M in toluene, 0.61 mL, 0.30 mmol). The mixture was stirred at
rt for 3 h, after which time TLC (10% EtOAc/hexanes) indicated complete consumption of
the starting material. The mixture was quenched with saturated aqueous NH4Cl (1 mL), the
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organic phase was separated, and the aqueous phase was extracted with EtOAc (3 x 1 mL).
The combined organics were dried over Na2SO4, filtered, concentrated, and used directly
in the next step. To a solution of this intermediate (309a) (49.0 mg, 84.5 µmol) in THF (1
mL) was added a solution of TBAF (1.00 M in THF, 127 µL, 0.127 mmol) at 0 ºC, and the
mixture was removed from the ice bath and stirred at rt for 2 h. LC-MS indicated that some
of the desired PMB ester product had been hydrolyzed to the carboxylic acid. The mixture
was concentrated, then 1 N aqueous HCl (2 mL) was added, and the solution was extracted
with EtOAc (3 x 2 mL). The combined organics were dried over Na2SO4, concentrated,
and re-dissolved in acetone (3 mL). To the solution was added PMBCl (9.2 µL, 0.0676
mmol), K2CO3 (14.0 mg, 0.101 mmol), and 5 to 10 crystals of TBAI, and the mixture was
stirred for 24 h at rt. TLC (100% EtOAc) indicated that the carboxylic acid was consumed.
The mixture was filtered through Celite and concentrated, then purified by chromatography
on a silica gel-packed Pasteur pipette (30–40% EtOAc/hexanes), to give 310a (15.9 mg,
55%) as a colorless oil. 1H NMR (300 MHz, CDCl3) δ 7.35 (d, J = 8.8 Hz, 2H), 6.89 (d, J
= 8.7 Hz, 2H), 5.26 (d, J = 11.9 Hz, 1H), 5.11 (d, J = 11.9 Hz, 1H), 5.01 (t, J = 2.6 Hz, 1H),
4.87 (t, J = 2.2 Hz, 1H), 3.81 (s, 3H), 3.76 – 3.63 (m, 1H), 3.60 – 3.44 (m, 1H), 3.10 (d, J
= 8.4 Hz, 1H), 2.98 (dq, J = 17.5, 2.0 Hz, 1H), 2.68 – 2.54 (m, 2H), 2.32 (t, J = 6.4 Hz,
1H), 2.12 – 1.97 (m, 1H), 1.84 (dd, J = 12.4, 3.6 Hz, 1H), 1.25 (s, 3H).

13

C NMR (101
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MHz, CDCl3) δ 172.5, 159.9, 147.1, 134.9, 130.5, 130.4, 129.7, 128.7, 127.8, 127.2,
123.4, 114.1, 114.1, 114.1, 114.0, 107.9, 67.4, 60.3, 60.2, 55.4, 50.8, 47.5, 45.0, 41.5, 36.2,
24.5. HRMS (ESI+): calcd for C20H23NNaO4 [M+Na]+ 364.1525; found 364.1530.

4-methoxybenzyl

2-cyano-2-ethyl-7-(hydroxymethyl)-5-

methylenebicyclo[2.2.1]heptane-1-carboxylate. 308 (20.0 mg, 33.7 µmol) was treated
following the procedure of 310a using EtI instead of MeI. 310b was obtained in 4.6 mg,
38% yield. 1H NMR (300 MHz, CDCl3) δ 7.35 (d, J = 8.8 Hz, 2H), 6.89 (d, J = 8.6 Hz,
2H), 5.22 (d, J = 11.9 Hz, 1H), 5.13 (d, J = 11.9 Hz, 1H), 5.02 (t, J = 2.6 Hz, 1H), 4.86 (t,
J = 2.2 Hz, 1H), 3.81 (d, J = 0.5 Hz, 3H), 3.70 (dd, J = 11.7, 7.4 Hz, 1H), 3.60 – 3.43 (m,
1H), 3.12 – 2.94 (m, 2H), 2.70 – 2.52 (m, 2H), 2.31 (t, J = 6.4 Hz, 1H), 1.97 – 1.81 (m,
2H), 1.50 – 1.34 (m, 2H), 0.98 (t, J = 7.3 Hz, 3H). 13C NMR (75 MHz, CDCl3) δ 172.7,
159.9, 147.2, 130.4, 127.2, 122.2, 114.1, 107.9, 67.3, 60.7, 60.3, 55.4, 51.3, 47.8, 47.7,
41.8, 36.6, 29.3, 8.9. HRMS (ESI+): calcd for C21H25NNaO4 [M+Na]+ 378.1681; found
378.1687.
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4-methoxybenzyl

2-benzyl-2-cyano-7-(hydroxymethyl)-5-

methylenebicyclo[2.2.1]heptane-1-carboxylate. 308 (20.0 mg, 33.7 µmol) was treated
following the procedure of 310a using BnBr instead of MeI. 310c was obtained in 12 mg,
85% yield. 1H NMR (400 MHz, CDCl3) δ 7.46 – 7.27 (comp, 5H), 7.23 – 7.13 (m, 2H),
6.96 – 6.82 (m, 2H), 5.28 (d, J = 11.8 Hz, 1H), 5.11 (d, J = 11.8 Hz, 1H), 4.97 (t, J = 2.6
Hz, 1H), 4.84 (t, J = 2.1 Hz, 1H), 3.77 (d, J = 0.9 Hz, 4H), 3.63 – 3.49 (m, 1H), 3.18 (s,
1H), 3.09 (d, J = 17.7 Hz, 1H), 2.75 – 2.55 (comp, 4H), 2.46 (t, J = 6.4 Hz, 1H), 2.07 (dd,
J = 13.1, 4.3 Hz, 1H), 1.56 (d, J = 13.1 Hz, 1H). 13C NMR (75 MHz, CDCl3) δ 172.5,
160.0, 147.0, 134.2, 130.6, 130.5, 128.6, 127.7, 127.2, 122.7, 114.2, 107.9, 67.4, 61.0, 60.3,
55.4, 51.4, 47.7, 47.1, 41.2, 41.0, 36.5. HRMS (ESI+): calcd for C26H27NNaO4 [M+Na]+
440.1838; found 440.1841.
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6-(2-chloroallyl)-9-oxa-6-azaspiro[4.5]decan-8-ol.

To

a

solution

of

(1-

aminocyclopentyl)methanol69 (3.10 g, 26.9 mmol) in EtOH (100 mL) was added 2,2dimethoxyacetaldehyde (60% in water, 4.47 mL, 29.6 mmol). The mixture was stirred at rt
for 18 h, after which time crude NMR indicated complete conversion to the intermediate
imine. The mixture was quenched with 50 mL 1 N aq. NaOH followed by 50 mL H2O, then
extracted with DCM (3 x 100 mL). The combined organics were dried over Na2SO4,
filtered, concentrated, and redissolved in Et2O (100 mL) in a flask sealed under N2. LiAlH4
(1.02 g, 26.9 mmol) was added, and the mixture was stirred at rt for 30 min. The reaction
was quenched by adding EtOAc (50 mL) and saturated aqueous Rochelle's salt (100 mL).
The organic phase was separated and the aqueous phase was extracted with EtOAc (3 x
100 mL). The combined organics were washed with brine (100 mL), dried over Na2SO4,
filtered, and concentrated to give a colorless oil. The intermediate amine was dissolved in
EtOH (60 mL) and 2,3-dichloroprop-1-ene (1.05 mL, 11.4 mol), NaHCO3 (2.00 g, 23.8
mol) and NaI (114 mg, 0.763 mmol) were added. The mixture was heated to 80 °C under
N2 atmosphere for 18 h, after which time crude NMR indicated about 10% conversion to
the desired product. Additional NaI (1.14 g, 7.63 mmol), NaHCO3 (2.00 g, 23.8 mol), 5 to
10 crystals of TBAI and 2,3-dichloroprop-1-ene (0.1 mL, 1.09 mmol) were added. The
mixture was refluxed at 87 °C under N2 atmosphere for 24 h, after which time crude NMR
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indicated about 80% conversion. The mixture was heated to 100 oC for another 2 h, then
filtered through Celite and concentrated to a yellow oil, which was dissolved in conc. HCl
(60 mL). The mixture was then refluxed at 105 °C under N2 atmosphere for 2 h, the solvent
was evaporated, and 6 N NaOH (30 mL) was added. The mixture was extracted
with EtOAc (3 x 30 mL), and the combined organics were washed with brine and dried
over Na2SO4, filtered, concentrated, and purified by chromatography (10–40%
EtOAc/hexanes) to give 47 (390 mg, 22% overall yield) as a colorless solid. 1H NMR (400
MHz, CDCl3) δ 5.40 (app q, J = 1.2 Hz, 1H), 5.30 (app q, J = 1.0 Hz, 1H), 4.94 (ddd, J =
9.0, 3.9, 2.2 Hz, 1H), 3.82 (d, J = 9.1 Hz, 1H), 3.69 (dd, J = 11.4, 1.2 Hz, 1H), 3.25 (dd, J
= 11.4, 0.7 Hz, 1H), 3.16 (dt, J = 15.0, 1.3 Hz, 1H), 2.96 (d, J = 14.8 Hz, 1H), 2.69 (dd, J
= 11.6, 2.2 Hz, 1H), 2.46 (dd, J = 11.6, 3.9 Hz, 1H), 1.86 – 1.30 (comp, 8H). 13C NMR
(101 MHz, CDCl3) δ 140.2, 114.2, 91.5, 69.4, 66.0, 56.4, 52.8, 31.7, 28.4, 25.9, 25.8.
HRMS (ESI+): calcd for C11H19ClNO2 [M+H] 232.1104; found 232.1106.

2-hydroxy-4-(4-methoxybenzyl)morpholin-3-one. A solution of 50 wt% aqueous
glyoxylic acid (9.14 g, 99.3 mmol) in THF (20 mL) was heated to reflux, then 2-(4-
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methoxybenzylamino)ethanol105 (6.00 g, 33.1 mmol) was added over 30 min, and the
reaction was refluxed for another 2 h. THF was distilled off under atmospheric pressure
while maintaining a constant volume by simultaneous addition of water (20 mL). The
mixture was cooled to rt, then placed in an ice bath for 30 min., where the product
crystallized. The solids were filtered with a Buchner funnel, washed with water, and then
dried under vacuum at 60 ºC for 24 h to give 48 (3.6 g, 46%) as a colorless solid. 1H NMR
(400 MHz, CDCl3) δ 7.20 (d, J = 7.0 Hz, 2H), 6.86 (d, J = 7.0 Hz, 2H), 5.34 (s, 1H), 4.91
(s, 1H), 4.65 (d, J = 14.4 Hz, 1H), 4.44 (d, J = 14.4 Hz, 1H), 4.30 – 4.18 (m, 1H), 3.80 (s,
3H), 3.78 – 3.74 (m, 1H), 3.42 (td, J = 11.2, 10.6, 3.9 Hz, 1H), 3.11 (d, J = 12.4 Hz, 1H).

7-(((-6-(2-chloroallyl)-9-oxa-6-azaspiro[4.5]decan-8-yl)oxy)methyl)-2-cyano-2methyl-5-methylenebicyclo[2.2.1]heptane-1-carboxylic acid. To a solution of 310a
(18.0 mg, 52.7 µmol) and PhNTf2 (20.7 mg, 58.0 µmol) in Et2O (1 mL), sealed under N2
and at –50 °C, was added KHMDS (0.5 M in toluene, 211 µL, 105 µmol), and the mixture

154

was stirred at the same temperature for 10 min. TLC indicated complete consumption of
the starting material (40% EtOAc/hexane). The mixture was quenched with aq. NH4Cl (1
mL) at the same temperature, then extracted with EtOAc (3 x 1 mL). The combined
organics were dried over Na2SO4, filtered, and concentrated to give the crude triflate, which
was used directly in the next step. To a solution of 47 (6.1 mg, 26 µmol) in DMF (0.2 mL)
was added NaH (60% in mineral oil, 3.4 mg, 88 µmol) at 0 °C. The mixture was stirred at
rt for 15 min., then a solution of the crude triflate in DMF (0.1 mL) was added. The mixture
was stirred at rt for 1 h, after which time LC-MS indicated complete consumption of the
starting material. The reaction was quenched with saturated aqueous NH4Cl (3 mL)
and extracted with EtOAc (3 x 3 mL). The combined organics were washed with
brine, dried over Na2SO4, filtered, concentrated, and purified by preparative HPLC to give
313a (3.3 mg, 43%) as a colorless oil. 1H NMR (300 MHz, CDCl3) δ 5.61 – 5.50 (m, 2H),
5.31 (d, J = 1.2 Hz, 2H), 5.11 – 5.02 (m, 2H), 4.94 (s, 2H), 4.59 (dd, J = 4.9, 2.7 Hz, 1H),
4.54 (dd, J = 5.5, 2.7 Hz, 1H), 4.08 (dd, J = 9.7, 5.7 Hz, 1H), 3.68 (d, J = 7.8 Hz, 2H), 3.59
(dd, J = 11.1, 3.8 Hz, 2H), 3.38 – 3.17 (m, 3H), 3.04 (d, J = 5.5 Hz, 5H), 2.97 (s, 1H), 2.84
(d, J = 3.9 Hz, 1H), 2.79 (d, J = 4.0 Hz, 1H), 2.72 – 2.64 (comp, 3H), 2.60 (d, J = 2.7 Hz,
1H), 2.44 (ddd, J = 11.7, 9.3, 5.1 Hz, 2H), 2.16 – 2.30 (comp, 12H, presumably obs w/
H2O), 2.13 (dd, J = 12.6, 2.3 Hz, 2H), 1.89 (dt, J = 12.7, 3.8 Hz, 2H), 1.59 (d, J = 10.5 Hz,
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6H), 1.51 (d, J = 1.0 Hz, 6H). 13C NMR (151 MHz, CDCl3) δ 172.4, 172.4, 147.2, 147.1,
140.1, 140.0, 123.4, 123.3, 113.3, 113.1, 108.6, 108.5, 98.7, 98.2, 70.8, 70.3, 68.1, 65.6,
65.5, 65.5, 65.3, 59.5, 59.5, 57.0, 56.9, 52.1, 52.0, 48.2, 48.1, 47.7, 47.6, 44.9, 44.9, 41.9,
41.8, 41.0, 36.2, 36.2, 29.9, 29.8, 25.8, 25.7, 25.0, 25.0, 22.9, 14.3. HRMS (ESI+): calcd
for C23H32ClN2O4 [M+H] 435.2051; found 435.2060; HPLC (Phenomenex Gemini C18)
(25% (0-1.5 min.) - 95% (3.5-10 min), MeCN/H2O; flow rate, 1.0 mL/min). RT= 7.30 min.

7-(((-6-(2-chloroallyl)-9-oxa-6-azaspiro[4.5]decan-8-yl)oxy)methyl)-2-cyano-2-ethyl5-methylenebicyclo[2.2.1]heptane-1-carboxylic acid. Following the same procedure of
313a using 310b (5.6 mg, 16 µmol) instead of 310a, 313b was obtained (1.5 mg, 20%). 1H
NMR (400 MHz, CDCl3) δ 5.60 – 5.52 (m, 2H), 5.30 (s, 2H), 5.10 – 5.05 (m, 2H), 4.94
(s, 2H), 4.61 – 4.56 (m, 1H), 4.54 (dd, J = 5.5, 2.7 Hz, 1H), 4.08 (dd, J = 9.7, 5.5 Hz, 1H),
3.81 (d, J = 1.0 Hz, 1H), 3.68 (d, J = 7.0 Hz, 2H), 3.58 (dd, J = 11.0, 4.5 Hz, 2H), 3.32 (t,
J = 9.2 Hz, 1H), 3.23 (dd, J = 16.4, 11.1 Hz, 2H), 3.13 – 2.96 (comp, 6H), 2.86 (s, 1H),
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2.80 (s, 1H), 2.71 – 2.56 (m, 2H), 2.49 – 2.35 (comp, 4H), 2.07 – 1.97 (m, 1H), 1.95 (t, J
= 3.1 Hz, 5H), 1.92 – 1.78 (m, 2H), 1.69 – 1.45 (comp, 16H, presumably obs w/ H2O), 1.28
(s, 1H), 1.15 – 1.04 (m, 6H). 13C NMR (151 MHz, CDCl3) δ 173.0, 147.2, 147.2, 140.1,
140.1, 133.8, 114.1, 113.3, 113.1, 108.6, 108.5, 98.8, 98.1, 76.9, 70.8, 70.2, 65.7, 65.5, 65.5,
65.3, 57.0, 56.9, 52.1, 52.0, 48.6, 48.0, 47.8, 47.8, 41.7, 41.6, 40.9, 37.1, 36.7, 36.7, 36.1,
32.1, 29.9, 29.8, 29.5, 29.5, 27.4, 25.8, 25.8, 25.8, 25.7, 22.9, 14.3. HRMS (ESI+): calcd
for C24H34ClN2O4 [M+H] 449.2207; found 449.2225; HPLC (Phenomenex Gemini C18)
(25% (0-1.5 min.) - 95% (3.5-10 min), MeCN/H2O; flow rate, 1.0 mL/min). RT= 7.06 min.

2-benzyl-7-(((-6-(2-chloroallyl)-9-oxa-6-azaspiro[4.5]decan-8-yl)oxy)methyl)-2cyano-5-methylenebicyclo[2.2.1]heptane-1-carboxylic acid. Following the same
procedure of 313a using 310c (7.8 mg, 19 µmol) instead of 310a, 313c was obtained (1.9
mg, 21%). 1H NMR (400 MHz, CDCl3) δ 7.38 – 7.27 (comp, 10H), 5.57 (s, 1H), 5.53 (s,
1H), 5.30 (s, 2H), 5.01 (d, J = 7.5 Hz, 2H), 4.89 (s, 2H), 4.64 – 4.58 (m, 1H), 4.57 – 4.50
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(m, 1H), 4.25 – 4.08 (m, 1H), 3.70 (dd, J = 20.1, 11.3 Hz, 2H), 3.59 (t, J = 10.7 Hz, 2H),
3.32 (t, J = 9.0 Hz, 1H), 3.26 (d, J = 11.1 Hz, 1H), 3.20 (dd, J = 12.3, 6.3 Hz, 2H), 3.14 –
2.96 (comp, 6H), 2.84 (s, 1H), 2.77 (s, 1H), 2.72 (d, J = 12.0 Hz, 1H), 2.69 – 2.63 (m, 2H),
2.62 (d, J = 0.7 Hz, 1H), 2.45 (ddd, J = 16.5, 12.8, 7.4 Hz, 5H), 2.14 – 2.02 (m, 2H), 1.57
(comp, 20H, presumably obs w/ H2O). HRMS (ESI+): calcd for C29H35ClN2O4 [M+H]
511.2364; found 511.2370; HPLC (Phenomenex Gemini C18) (25% (0-1.5 min.) - 95%
(3.5-10 min), MeCN/H2O; flow rate, 1.0 mL/min). RT= 8.27 min.

2-cyano-7-(((-4-(4-methoxybenzyl)-3-oxomorpholin-2-yl)oxy)methyl)-2-methyl-5methylenebicyclo[2.2.1]heptane-1-carboxylic acid. 310a (6.0 mg, 17.6 µmol) was
treated following the same procedure of 313a using 315 instead of 314, 312 was obtained
in 1.5 mg, 19% yield. 1H NMR (400 MHz, CD3OD) δ 7.18 (d, J = 8.1 Hz, 2H), 6.87 (d, J
= 8.1 Hz, 2H), 5.10 – 4.95 (m, 1H), 4.94 – 4.80 (m, 1H), 4.63 (t, J = 15.7 Hz, 1H), 4.37 (t,
J = 16.0 Hz, 1H), 4.24 – 3.89 (m, 2H), 3.72 – 3.60 (m, 1H), 3.42 (td, J = 12.4, 11.7, 4.8 Hz,
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1H), 3.09 (d, J = 12.6 Hz, 1H), 2.93 – 2.75 (m, 2H), 2.44 (d, J = 17.8 Hz, 1H), 2.31 (d, J =
9.9 Hz, 1H), 2.03 – 1.82 (m, 2H), 1.58 (s, 0H), 1.45 (s, 3H), 1.36 – 1.13 (comp, 5H). 13C
NMR (151 MHz, CD3OD) δ 174.1, 174.0, 166.3, 166.2, 160.9, 160.9, 150.0, 150.0, 130.7,
130.6, 129.2, 124.8, 124.8, 115.2, 115.1, 108.4, 108.2, 97.9, 97.0, 91.7, 67.8, 67.6, 67.0,
60.8, 57.9, 57.9, 50.0, 49.7, 46.6, 46.4, 46.1, 45.9, 42.6, 37.3, 33.1, 30.6, 30.5, 30.3, 30.2,
28.1, 26.9, 25.1, 25.0, 23.8. HRMS (ESI+): calcd for C24H28N2NaO6 [M+Na]+ 463.1845;
found 463.1855, HPLC (Phenomenex Gemini C18) (25% (0-1.5 min.) - 95% (3.5-10 min),
MeCN/H2O; flow rate, 1.0 mL/min). RT= 8.10 min.

4.4 Docking Studies

Representative procedure: (Molecular Forecaster, version 5263) In the Docking small
molecules to proteins module of the main UI, PDB file 1N0U was introduced. In the
PREPARE module, the ligand molecule Residue SO1 A 843 from the PDB file was selected
and other parameters were kept unchanged. In the PROCESS module, the prepare for
parameter was set to docking to rigid protein, other parameters were unchanged. In the
SMART module, a mol2 file containing the structure of interests was used as the source of
ligand structure, other parameters were unchanged. Then in the main UI, the Run workflow
bottom was clicked to start the calculation. The output sdf files were then visualized in
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Pymol.

4.5 Antifungal Assay

The isomeric mixtures 306, 312 and 313a–c were subjected to antifungal
microdilution assays using Clinical and Laboratory Standards Institute methods M27-A3
and M38-A2 at the Fungus Testing Laboratory at the University of Texas Health Science
Center at San Antonio. No inhibition of fungal growth was observed at up to 8 μg/mL, or
4 μg/mL (313c), against C. albicans (isolate# CA1, CA2, CA3), A. fumigatus (isolate# AF1,
AF2, AF3), C. parapsilosis (CLSI QC), and P. variotii (CLSI QC). Minimum inhibitory
concentrations (MICs) were determined after 24 h or 48 h (A. fumigatus), using fluconazole
and voriconazole as positive controls. For comparison, sordarin itself has a reported MIC
of 16 μg/mL vs wild type C. albicans (strain A28235),106 and the azasordarin 123 was
<0.008 μg/mL.40
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